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ABSTRACT 
Estrogens are key players in the etiology and progression of breast cancer, and mediate their 
effects through the estrogen receptors (ERα and ERβ). ERα plays important roles in 
proliferation and progression of breast cancer, whereas a distinct function of ERβ in the 
initiation and development of breast cancer is not yet clearly established. The general aim of 
this thesis was to increase our understanding of the molecular and cellular mechanisms of 
estrogen signalling in the normal and cancerous breast, focusing on the potential anti-
tumourigenic effect of ERβ. Using cell lines with endogenous expression or inducible 
expression of ERβ we have characterised possible pathways of how ERβ could mediate its anti-
tumourigenic effects.  
The role of ERβ in cell proliferation and cell cycle regulation has been 
characterised, mainly in vitro. In paper I we investigated how ERβ re-expression would affect 
breast cancer cells in in vivo. Presence of ERβ in breast cancer xenografts reduced tumour 
growth and the number of intratumoural blood vessels. Expression of the pro-angiogenic 
growth factors vascular endothelial growth factor and platelet-derived growth factor β were also 
reduced upon ERβ expression, both in vitro and in vivo. These findings suggested an anti-
tumourigenic role for ERβ by inhibiting growth and angiogenesis. 
Studies in ERβ-/- mice have suggested a role for ERβ in the regulation of cell 
adhesion. In paper II we looked at cell-cell adhesion with a focus on E-cadherin. We reported 
that decrease of ERβ in mammary epithelial cells was associated with a decrease of E-cadherin 
protein levels through different posttranscriptional regulatory mechanisms, including protein 
shedding, internalisation and degradation. This correlated with an increase in β-catenin 
transcriptional activity and impaired morphogenesis on Engelbreth-Holm-Swarm matrix. This 
study suggests that ERβ has an important role in maintaining cell adhesion and a differentiated 
phenotype. 
In paper III we analysed the effects of ERβ on cell-extracellular matrix 
adhesion. We found that integrin α1 and integrin β1 levels increased in breast cancer cells 
following ERβ expression. Also, the formation of vinculin containing focal complexes and 
actin filaments was enhanced, correlating to a more adhesive potential as seen by adhesion to 
ECM proteins. Furthermore, the migratory potential of the breast cancer cells was decreased 
upon ERβ expression. This study indicates that ERβ affects integrin expression and clustering 
and consequently adhesion and migration of breast cancer cells. 
ERβ has been implicated as an indicator of endocrine response in breast cancer. 
In paper IV we investigated if ERβ could modulate pathways implicated in endocrine 
resistance development. Expression of ERβ in human breast cancer cells resulted in a decrease 
in both active Akt, as well as its upstream regulator, the epidermal growth factor receptor 2 and 
3 (HER2/HER3) dimer. Expression of the tumour suppressor and important inhibitor of Akt 
signalling, PTEN was increased upon expression of ERβ. Further, ERβ expressing breast cancer 
cells had also an increased sensitivity to tamoxifen. In all, these data provide a possible 
mechanistic insight into how ERβ may contribute to endocrine sensitivity. 
In conclusion, the studies presented in this thesis contribute to the knowledge of 
ERβ function in normal and cancerous breast, and highlight several possible anti-tumourigenic 
mechanisms for ERβ. Although the mechanisms have not yet been fully characterised, in breast 
cancer, ERβ seems to affect growth, adhesion, angiogenesis and sensitivity to endocrine 
therapy. These studies highlight the importance of ERβ as a prospective prognostic marker with 
potential as a target in the treatment of breast cancer. 
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1 INTRODUCTION 
 
1.1 ESTROGEN RECEPTOR SIGNALLING 
 
1.1.1 Estrogen 
Estrogens are a class of sex steroid hormones, synthesized from the common precursor 
cholesterol [1]. The three major estrogens include 17β-estradiol (E2), which is the most 
potent hormone, and its metabolites estrone (E1) and estriol (E3). The enzyme 
cytochrome P-450 aromatase catalyses the last step in the biosynthesis of androgens to 
estrogens. Aromatase is located in the endoplasmic reticulum of estrogen-producing 
cells. The main estrogen production occurs in the ovaries, and to a lesser extent in the 
adrenal glands, adipose tissue, brain and testis. After menopause the ovarian production 
of estrogen declines, and the adrenal cortex and ovaries secrete mostly androgens, 
which are converted to estrogens in the peripheral tissues, such as adipose tissue and 
muscle [2]. Estrogens are involved in many physiological processes such as growth, 
differentiation, and functioning of reproductive tissues, but they also have important 
actions on other systems, such as bone, liver, cardiovascular system and brain. Loss of 
estrogen is usually associated with a rise in low-density lipoprotein (LDL), hot flushes 
and night sweats, and an increase in bone loss [3]. Aberrant estrogen signalling is 
associated with many human diseases such as cancer, osteoporosis, Parkinson’s and 
schizophrenia [4-6]. Estrogens biological action is mediated through the estrogen 
receptors (ERs).  
 
 
1.1.2 Estrogen receptors 
Estrogen receptors are members of the steroid receptor gene superfamily of nuclear 
receptors. Two ERs, ERα and ERβ have been identified. ERα was identified in the late 
1950s, however it was not until 1986 that ERα was cloned and sequenced from MCF-7 
human breast cancer cells [7]. Ten years later ERβ was identified and cloned [8]. ERα 
and ERβ are present in many of the same tissues, but differences in organ and tissue 
distribution, as well as in levels of expression, have been reported. ERα is mainly 
expressed in uterus, ovary (theca cells), bone, prostate (stroma), white adipose tissue, 
kidney, testis (Leydig cells), epididymis, breast, liver, skeletal muscle and various 
regions of the brain, whereas ERβ is mainly expressed in prostate (epithelium), ovary 
(granulosa cells), lung, testis, epididymis, bone marrow, salivary gland, regions of the 
brain, urogenital tract and intestinal epithelium [9, 10]. 
ERα and ERβ have five distinguishable domains, A/B, C, D, E and F 
(Fig. 1) [11]. The N-terminal A/B domain contains the activator function 1 (AF-1) 
domain, which is constitutively active and mediates ligand independent transcriptional 
activation. Comparison of ERα and ERβ AF-1 domain has revealed that ERβ has a 
weak AF-1 function compared to ERα [12]. In addition, the N-terminal region is 
involved in interactions with co-regulators. Also, phosphorylation sites for different 
kinases are present in the AF-1 domain of both ERα and ERβ, resulting in stimulation 
of AF-1 activity [13-19]. The A/B domain shares the least homology between the 
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receptors, suggesting that this domain contributes to ER specific subtype actions on 
target genes.  
The C domain harbours the DNA binding domain, mediating sequence 
specific DNA binding. Although ERα and ERβ are products of distinct genes - ERα is 
located on chromosome 6, while ERβ is located on chromosome 14 [20, 21] - they 
share relatively high degrees of homology in the DNA binding domain, approximately 
97%.  ChIP-on-chip analysis has shown that there is a high degree of overlap between 
DNA regions bound by ERα and ERβ respectively. However, there are also DNA 
regions preferentially bound by ERα or ERβ, as well as regions in which ERα binds 
only in the presence of ERβ. ERα binding sites have overrepresentation of TA-rich 
motifs and forkhead transcription factor binding sites, whereas ERβ binding regions are 
more closely located to transcription start sites and have a predominance of classical 
estrogen response elements (EREs) and GC-rich motifs, thereby explaining the 
differences in gene expression and effects by each respective ER [22]. 
 
 
 
 
 
 
 
 
 
 
Figure 1. Structure and degree of homology between ERα and ERβ. The A/B domain 
contains the ligand-independent transcription activation function-1 (AF-1), and sites 
for phosphorylation. The C domain mediates DNA binding. The D domain joins the C 
and E domain and contains nuclear localisation sequences. The E domain contains the 
ligand-dependent transcription activation function-2 (AF-2) and is involved in ligand 
binding. The F-domain is involved in co-regulator recruitment. Full-length ERα is 595 
amino acids long, whereas ERβ contains 530 amino acids. Homology at the amino acid 
level is indicated in %. 
 
 
The D (hinge) domain joins the E/F-domain with the C-domain, and 
contains nuclear localisation sequences [23]. 
The E domain contains the ligand binding domain and the ligand-
dependent transactivation AF-2 domain. This domain is also involved in nuclear 
translocation, co-factor binding, and receptor homo/hetero dimerisation, as well as 
interactions with heat shock proteins. Although both ERα and ERβ bind to 17β-
estradiol with the same affinity, their ligand binding domains only have 56% amino 
acid identity [9], suggesting that ligands may be developed which have different 
affinities for the two ERs. 
The carboxy terminus F domain seems to have a modulatory role for 
receptor transcription activity and recruitment of co-regulators [24, 25]. 
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1.1.3 Estrogen receptor signalling 
In their unliganded state, ERs are associated with inhibitory protein 
complexes of heat shock proteins, repressing their function [26]. Upon ligand binding, 
the ER conformation is altered and the receptors dissociate from the inhibitory 
complex, triggering receptor dimerisation, recruitment of co-regulators, and binding of 
the receptor complex to promoter regions of target genes. The co-regulators can either 
stimulate (co-activators) or inhibit transcription (co-repressors). The co-activators, the 
SRC family and p300/CBP-associated factor, have intrinsic histone acetylase (HAT) 
activity, whereas the co-repressors, such as SMRT and NCoR, recruit histone 
deacetylases (HDACs). These result in the alteration of chromatin structure, thereby 
facilitating or blocking, respectively, the recruitment of the RNA-polymerase 
machinery to the promoter [27-29]. 
Various mechanisms for ER transcriptional regulation have been 
described (Fig. 2). The classical mechanism involves direct binding of ER dimers to 
DNA with classical EREs, either as homo- or heterodimers. Non-classical mechanisms 
involve regulatory interactions with other transcriptional complexes, such as activator 
protein-1 (AP-1) and specificity protein-1 (SP-1) [30, 31], and thereby resulting in an 
indirect binding to DNA. ERα and ERβ signal in opposite ways on AP-1 driven 
promoters in the presence of E2, where ERα activates transcription and ERβ inhibits 
transcription. In contrast, anti-estrogens all increase AP-1 activity of both ERs [32]. 
 
Figure 2. ER signalling mechanisms. I The classical pathway involves ligand binding 
of 17β-estradiol (E2), and activation of the receptor, followed by direct binding to 
estrogen response elements (EREs). II The non-classical pathway involves protein-
protein interactions with other transcription factors (TF), followed by indirect DNA 
binding to response elements (RE). III Ligand-independent ER signalling involves 
growth factor (GF) signalling and phosphorylation and subsequent activation of the 
receptor. IV The non-genomic pathway involves rapid estrogenic effects involving 
membrane localised ER or other distinct receptors. The example shows ER binding to 
phosphatidylinositol 3-kinase (PI3K) resulting in an increase of nitric oxide (NO) 
levels in the cytoplasm. 
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In addition, E2 have so-called non-genomic effects outside the nucleus. 
These are very rapid responses, occurring within seconds or minutes after addition of 
E2, and therefore do not involve new synthesis of mRNA or protein [33]. These actions 
involve membrane located ERs [34] or other distinct receptors [35], where ligand 
activation results in signalling cascades including activation of kinases, phosphatases 
and increases in ion fluxes across membranes, consequently leading to physiological 
responses. Examples include changes in intracellular calcium [36], increases in cAMP 
[37], and activation of membrane-associated enzymes, as described in Fig. 2 – section 
IV, where ERα has been shown to bind to the p85α regulatory subunit of 
phosphatidylinositol 3-kinase (PI3K), leading to activation of Akt and endothelial nitric 
oxide synthase (eNOS). This results in an increase of nitric oxide (NO) levels in the 
cytoplasm [38]. Posttranslational modifications such as phosphorylation, acetylation, 
SUMOylation, ubiquitinylation and methylation can also modulate the transcriptional 
activity of ERs [1]. 
ER activities have been presumed to require ligands, but several growth 
factors have been shown to stimulate ER activity in absence of ligand, mediated by the 
phosphorylation of the receptor by different kinases resulting in its activation [13-19]. 
Ligand independent activation of ER was first suggested in the early 1990s, where 
nuclear translocation and transcriptional activation of ER was observed in 
ovariectomized mice treated with epidermal growth factor (EGF) [39]. Since then, 
pathways and mechanisms involved in ligand independent activation have emerged but 
are not fully characterized. 
 
 
1.1.4 Estrogen receptor ligands 
The discovery of the second estrogen receptor isoform (ERβ) encouraged the search for 
ligands selective for either ERα or ERβ to allow investigation of the biological function 
of each ER in vitro and in vivo. Selectivity of ligand action has been possible due to 
differences in ERα and ERβ tissue distribution and since the ligand binding domains 
only have 56% amino acid sequence identity. Altogether, this has made it possible to 
develop agonists and antagonists with different affinities and potencies for each ER, 
which is of therapeutic value for treatment of estrogen-linked diseases. Today several 
selective agonists/antagonists with isoform selective affinity (Fig. 3) exist.  
ERα and ERβ bind to E2 with comparable affinity [10]. The most used 
selective ligand for ERα is tetrasubstituted propylpyrazole (PPT). It has a 410-fold 
binding selectivity for ERα versus ERβ and activates gene transcription only through 
ERα [40]. PPT has also been shown to have similar effects as E2 in many tissues [41]. 
Known used ERβ agonists include diarylpropionitril (DPN), 7-bromo-2-
(4-hydroxyphenyl)-1,3-benzoxazol-5-ol (WAY 200070), and the phytoestrogens 
coumestrol, and genistein, which have ERβ binding selectivies of 70-, 68-, 3-, and 19-
fold, respectively [10, 42, 43]. Phytoestrogens are plant-derived chemicals with 
estrogenic activity and are classified according to their chemical structure: isoflavones, 
flavones, flavanones, coumestans, stilbenes, and lignans. Isoflavones are the most 
studied phytoestrogens, present in high concentrations in soy products and red clover 
[44]. In countries with a high intake of phytoestrogens there is a lower incidence of 
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breast cancer, suggesting that phytoestrogens may have a protective role in breast 
carcinogenesis through its preference for ERβ [45-48]. 
 A variety of synthetic estrogen antagonists have been developed. These 
include selective estrogen receptor modulators (SERMs), including tamoxifen and 
raloxifene. Tamoxifen is metabolised in the liver to its active metabolite 4-
hydroxytamoxifen. Unlike estrogens which are uniformly agonists, SERMs function as 
ER antagonists in some tissues, like breast and brain, agonists in other tissues, such as 
the heart and bone, and mixed ER agonists/antagonists in the uterus [49]. Selective 
estrogen receptor downregulators (SERDs) like ICI 182,780 (ICI) are pure antagonists 
and exhibit no agonist activity in any tissue yet measured.  
The response of the ERs to the synthetic anti-estrogens tamoxifen and 
raloxifene as measured with ERE reporters are different. Together with ERα these 
ligands are partial E2 agonists, whereas with ERβ they are pure ER antagonists [50-52]. 
The difference in the N-terminal region is a possible explanation for these differences. 
Furthermore, when ERα and ERβ are co-expressed under experimental conditions, it 
has been shown that they form heterodimers preferentially over homodimers [53], and 
with an increase in the relative ERβ/ERα ratio in a cell, repression of ERα-mediated 
partial agonistic activity in response to tamoxifen is seen [12, 54]. Thus, depending on 
heterodimerisation or homodimerisation, differences in receptor activities and selection 
of target genes can be seen [55-58].  
 
 
 
Figure 3. Estrogen receptor ligands 
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1.2 ESTROGEN RECEPTORS IN HEALTH AND DISEASE 
 
1.2.1 Breast Cancer 
Breast cancer is the most frequently diagnosed cancer in women. Women of the 
Western world have 12% lifetime risk of developing breast cancer, where 
approximately 25% of women diagnosed will die from the disease due to metastases. In 
Sweden, approximately 15-20 women are diagnosed every day. Approximately two-
thirds of breast cancers occur when ovarian estrogens are no longer produced, that is 
during the postmenopausal period. Although much less common, men can also develop 
breast cancer with approximately 40 men in Sweden diagnosed every year. The 
treatment and prognosis is the same as for women [59]. 
Breast cancer arises in the ductal and lobular epithelium of the mammary 
gland. As most breast cancers, at least initially, are dependent on estrogen – 
approximately 60% in premenopausal women, and 75% in postmenopausal women 
[60, 61], blockers of estrogen action are important drugs in its treatment. Estrogen-
independent breast cancers follow a more aggressive clinical course than the estrogen-
dependent breast cancers.  
Breast cancer is a heterogeneous disease, and can be divided into four 
molecular classes on the basis of ER status, where luminal A and B are ER positive 
subtypes, whereas ER negative breast tumours include HER2 overexpressing and 
basal-like subtypes. Basal-like subtype is the most aggressive type of the disease, and 
has the worst outcome. This subtype is negative for ER, progesterone receptor (PR) and 
HER2. Tumour grade can discriminate luminal A from luminal B tumours, where 
luminal A cancers have low histological grade, whereas luminal B tumours have high 
histological grade. 
The incidence of breast cancer has increased during the last 50 years. The 
reasons behind this are unclear, however, improved diagnostic methods could 
contribute to this. Other reasons could be increased carcinogenic factors in the diet, as 
well as environmental pollutants, some of which have shown affinity for ERs. Since 
estrogen plays a crucial role in most breast cancers in women, early menarche, late 
menopause and a low number of pregnancies are also correlated to an increased risk for 
breast cancer, due to greater number of menstrual cycles, and therefore larger amounts 
of circulating sex hormones during the life time. Obesity is also correlated to increased 
risk due to estrogen synthesis in the adipose tissue, whereas early pregnancy and breast 
feeding decreases the risk of breast cancer, due to lower levels of hormones and due to 
development of a fully differentiated mammary gland [62]. About 5-10% of breast 
cancers are thought to be hereditary, where the most common cause is inherited 
mutations in BRCA1 and BRCA2 genes. The risk may be as high as 80% in carriers of 
BRCA mutations. Women who inherit these mutations are usually young when breast 
cancer develops and often both breasts are affected. These mutations also increase the 
risk for developing other cancers, particularly ovarian cancer [63].  
The management of breast cancer has improved dramatically over the 
recent decades due to earlier detection, and new therapeutic strategies. But still there 
are challenges in breast cancer treatment and thus it is important to explore new 
possible therapeutic strategies, find better prognostic markers, and circumvent 
endocrine resistant tumour growth. 
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1.2.2 Estrogen receptors in the normal and cancerous breast 
Estrogen is a critical regulator of breast epithelial cell proliferation, differentiation and 
apoptosis. Females deficient in aromatase cannot convert androgens to estrogens, and 
do not develop breasts at puberty. However, estrogen replacement therapy in these 
females results in normal breast development [64]. Knockout mice for the two ERs 
have revealed the importance of these receptors in vivo, where ERα has been shown to 
be essential for normal mammary gland development and function, whereas ERβ is 
important for the terminal differentiation of the mammary gland [65]. ERα is expressed 
in 7-10% of luminal epithelial cells in the normal human breast, and its expression 
fluctuates with the menstrual cycle [66-68]. In contrast, ERβ expression is high in the 
normal breast, 80-85% of cells and does not fluctuate during the menstrual cycle [69, 
70].  
Estrogen plays an important role not only in development of normal 
mammary glands but also in the cancerous breast, where aberrant signalling leads to 
proliferation and progression of breast cancer. E2 treatment of breast cancer cells 
stimulates proliferation in vitro, and growth of tumour cell xenografts in mice [33].  
The ERs are crucial mediators of estrogen function and have important roles in 
carcinogenesis. Therefore, both estrogen synthesis and ER actions have been targeted 
by therapies to control hormone dependent breast cancers. ERβ is often lost during 
carcinogenesis, whereas ERα expression in increased, suggesting a possible tumour 
suppressor role for ERβ. ERα promotes proliferation, whereas ERβ has been shown to 
suppress ERα transcriptional activity and  lower expression of ERα target genes, e. g. 
pS2, cyclin D1 and PR [71, 72], and to promote anti-proliferative and pro-apoptotic 
functions as well as decrease motility [73-76]. Due to its decreased expression, ERβ:s 
ability to modulate ERα is altered during tumourigenesis [69, 77], and this may 
contribute to the pathogenesis of breast cancer. 
The majority of breast cancers express ERα, approximately 70%, 
providing a predictive value for endocrine therapy, such as treatment with tamoxifen 
and aromatase inhibitors. Those tumours expressing both ERα and PR have the greatest 
benefit from endocrine therapy [78]. In general, ERα expression is associated with low 
tumour grade, long disease-free survival and high overall survival. ERα positive 
tumours are also less invasive. In contrast, loss of ERα is associated with poor 
prognosis, elevated incidence of metastasis and increased recurrence [79]. The 
significance of ERβ is still under debate. Loss of ERβ has  been associated with a more 
invasive phenotype, poor survival and tamoxifen resistance, and its expression is 
associated with a better disease outcome and tamoxifen sensitivity [80]. In addition, 
when ERβ is phosphorylated at serine 105, it is associated with better survival, and 
phosphorylated ERβ could therefore be used as a prognostic marker [81]. This 
phosphorylation could implicate ligand-independent activation of the receptor. Altered 
expression of ER co-factors has  also been reported during breast tumourigenesis, 
where SRC-3 has  been reported to be overexpressed in breast cancer and contribute to 
endocrine resistance, by reducing the antagonist activity of tamoxifen [82, 83].  
Interestingly, in breast cancer cells, ERβ promoter region has been found 
to be hypermethylated compared to normal breast epithelial cells. This 
hypermethylation was inversely correlated to ERβ mRNA levels. Treatment with a 
demethylating agent reactivated ERβ expression, suggesting one possible mechanism 
for the described disappearance of ERβ in breast cancer. These observations from cell 
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lines were also reflected in primary breast cancer tumours [84]. Increased promoter 
methylation has also been noted in premalignant lesions and in approximately 60% of 
invasive breast cancers, corresponding to poor clinical prognosis [85]. Regarding ERα, 
its expression levels have also been shown to be regulated by DNA methylation. 
Hypermethylation of ERα promoter is associated with a decrease in mRNA levels and 
inhibition of DNA methyltransferases reactivates ERα expression [86]. 
 Crosstalk between ER and growth factor pathways may also contribute to 
breast cancer since growth factors can activate ERs independently of hormone, e.g. 
EGF has been shown to activate both ERβ and ERα via MAPK phosphorylations [17, 
87]. Constitutive activation of the PI3K pathway and overexpression of HER2 also 
activates ERα [15, 88]. These crosstalks may provide alternative growth pathways for 
tumours. 
 
 
1.2.3 Endocrine therapy 
During recent years, new cancer therapies have emerged that inhibit specific pathways 
important for tumour growth, however endocrine therapy is the most efficient treatment 
in estrogen receptor positive breast cancers. Endocrine therapy blocks the action of 
estrogen on tumour cells by either inhibiting estrogen binding to its receptors or its 
synthesis. Mortality from breast cancer is decreased when using endocrine therapies 
[89], but their efficacy is limited by intrinsic and acquired therapeutic resistance. 
Early breast cancer therapies included surgical removal of the ovaries, but 
during the 1970s, the synthesis of competitive inhibitors of estrogen-ER binding led to 
targeted cancer therapy, especially the SERM tamoxifen [90]. Later, development of 
other effective endocrine therapies involved targeting estrogen synthesis, such as 
aromatase inhibitors (AIs) [91], or ER signalling, such as other SERMs (raloxifene) and 
anti-estrogens (ICI) [92, 93].  
ERα positive breast cancers represent the majority of breast cancer cases, 
therefore, ERα has been the major therapy target for decades. Tamoxifen has been used 
in endocrine therapy for the last 25 years, and is therefore the most well studied anti-
estrogen. It binds to ER, thereby preventing estrogen binding, and alters the receptor 
conformation, leading to co-repressor recruitment, inhibition of AF-2 activation, and as 
a result, transcriptional activation is blocked. However, the AF-1 domain remains 
active in the presence of tamoxifen [94]. Tamoxifen has also been used as preventive 
treatment in patients with high risk of developing breast cancer [95]. Tamoxifen 
displays partial agonist-antagonist activities in different tissues and cells, related to the 
environment of ER co-activators and co-repressors in these tissues. It acts as an 
antagonist in the breast whereas in the bone and cardiovascular system it functions as 
an agonist. Therefore, tamoxifen promotes beneficial effects such as reducing the risk 
of osteoporosis. The agonistic properties of tamoxifen is enhanced in cells with 
increased levels of co-activators such as SRC3 or SRC1 [96]. However, long-term 
treatment with tamoxifen is associated with an increased risk of endometrial cancer, 
blood clots and stroke [95].  
Raloxifene, the second generation SERM, is similar to tamoxifen, in that 
it acts as an estrogen antagonist in breast tissue by competitive binding to ER. 
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Raloxifene is approved for breast cancer prevention, but not for treatment [97]. 
Raloxifene is also used to prevent and treat osteoporosis in women after menopause. 
The SERD ICI binds and promotes degradation of the receptor through 
the ubiquitin-proteasome pathway [98]. The downregulation of ER in the presence of 
SERDs, completely inhibits ER-mediated gene transcription by inactivating both AF-1 
and AF-2 domains [99]. ICI is used to treat ER-positive breast cancer patients who fail 
to respond to tamoxifen. No agonistic effects are observed with ICI [100]. 
Aromatase inhibitors (AIs), block the production of estrogens by 
inhibiting the enzyme aromatase that converts androgens to estrogens [101], thereby 
suppressing both tumour and plasma estrogen levels. AIs offer some benefits over 
tamoxifen in postmenopausal women with estrogen-dependent breast cancers [102, 
103], however acquired resistance after an initial response commonly occurs. In 
tumours with ER, SRC3 and HER2 expression, tamoxifen has been shown to act as an 
agonist and stimulates tumour growth [104], suggesting that aromatase inhibitors might 
be more effective in such patients, which is also supported by clinical studies [105, 
106].  
Despite the development of new therapeutic treatments, resistance to all 
forms of endocrine therapy exists, and therefore limits our ability to take full advantage 
of endocrine treatments for breast cancer. Thus important challenges within breast 
cancer research include characterising the factors and pathways responsible and 
identifying solutions how to overcome this resistance.  
 
 
1.2.4 Endocrine resistance 
Approximately 30% of ERα-positive tumours fail to respond to endocrine therapy 
[107], and therefore it is of great importance to develop more specific biomarkers that 
predict the therapeutic response to endocrine therapy and to identify new therapeutic 
targets for endocrine resistant disease. Resistance to endocrine therapy in ER-positive 
tumours can be classified as either intrinsic, i.e. resistance occurs de novo at the initial 
exposure to endocrine therapy, or as acquired, i.e. the resistance manifests over time. 
The lack of expression of ERα is the primary mechanism behind intrinsic 
resistance to tamoxifen, but it has also been documented recently that patients carrying 
inactive alleles of cytochrome P450 2D6 (CYP2D6), fail to convert tamoxifen to its 
active metabolite, endoxifen, and as a consequence, are less responsive to tamoxifen. 
This is seen in approximately 8% of Caucasian women [108]. Regarding acquired 
resistance, several mechanisms have been postulated, as described below.  
 
I. Estrogen receptors: Initially, loss of ERα expression or occurrence of ERα 
mutations was suggested to be implicated in acquired resistance. However, loss of 
ERα expression occurs only in a minority (15-20%) of breast cancers [109], and 
less than 1% of ER positive tumours have mutations in ERα [110]. More recently, 
truncated isoforms of ERα and ERβ [111, 112], as well as post-translational 
modifications of ERα, have been suggested to contribute to endocrine resistance, 
where phosphorylation of the receptor has been shown to change the pharmacology 
of the receptor, resulting in ligand-independent or tamoxifen mediated activation of 
the receptor [15, 113]. Increased transcriptional activity of activator protein 1 (AP-
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1), and nuclear factor κB (NFκB) is also associated with endocrine resistance [114]. 
Furthermore, overexpression and increased phosphorylation of co-activators, such 
as SRC3, leads to constitutive ER-activated transcription and is associated with 
reduced responsiveness to tamoxifen in patients [83]. Not much is known about 
ERβ function in endocrine resistance, but recent studies have shown that reduced 
levels of ERβ is associated with resistance to tamoxifen therapy [115], and 
therefore insight into ERβ relation to endocrine resistance is of importance. 
 
II. Growth factor signalling pathways: Crosstalk between receptor tyrosine kinases 
(RTKs) and ER signalling has been shown to promote resistance to endocrine 
therapy. The RTKs are responsible for persistent ER activity by activation of 
MAPK and Akt, with subsequent phosphorylation and activation of the ERs. This 
activation results in increased expression of ER responsive genes, such as 
amphiregulin, an epidermal growth factor receptor (EGFR) ligand, thereby creating 
an ability to maintain cell growth and proliferation despite endocrine therapies, (by 
activation of RTK pathways) [116]. Furthermore, HER2 signalling can be activated 
by membrane ER, and the kinase cascade downstream of HER2 can activate ER 
and its coregulatory proteins [104]. In all, activated RTKs result in limited efficacy 
to endocrine therapy, explaining why tamoxifen is less effective in HER2 and 
EGFR positive tumours [83, 117-120]. The importance of HER3 in the 
development of the hormone resistant phenotype is recently beginning to be 
understood. In MCF-7 cells transfected with heregulin cDNA, the ligand for HER3, 
the cells become estrogen independent and resistant to anti-estrogens, both in vitro 
and in vivo [121]. In addition, siRNA against HER3, abrogates HER2 mediated 
tamoxifen resistance in breast cancer cells [122]. HER2 and HER3 positive breast 
cancer patients are also more prone to relapse on tamoxifen [123], suggesting that 
HER3 and its ligands are good potential targets for modulating tamoxifen 
resistance. Increased activity of Akt signalling pathway, one of the downstream 
effectors of EGFR family, is also associated with  tamoxifen resistance [124-126], 
and knockdown of phosphatase and tensin homologue deleted on chromosome 10 
(PTEN), the negative regulator of Akt, in estrogen-positive breast cancer cell lines, 
results in anti-estrogen resistance and hormone independent growth [127]. This 
further strengthens the connection between RTK/PI3K/Akt signalling pathway and 
estrogen receptors in resistance to endocrine therapy. Recent observations also 
suggest a reversible phenotype of breast cancer cells, where some ER-negative 
tumours that overexpress HER2, become ER-positive after anti-HER2 therapy 
[128, 129].  
 
III. Alterations in the intracellular pharmacology: Drug-metabolising enzymes 
(DME) play key roles in the activation and deactivation of drugs. Therefore, 
increased/defective metabolism of a drug will influence its toxic and therapeutic 
effects on the tumour. The use of serotonin reuptake inhibitors, to treat hot flushes 
in women, are known to inhibit CYP2D6 [130], thereby resulting in a reduced 
response to tamoxifen. Overexpression of co-activators and/or downregulation of 
co-repressors can also abrogate the effect of SERMs [96]. Furthermore, the tumour 
can develop resistance by active drug efflux by membrane transporters, such as 
multidrug resistance-associated proteins (MRPs) [131].  
 11 
 
The knowledge behind the mechanisms of why breast cancer cells 
become resistant to endocrine therapy is increasing and several potential good targets 
have been discovered. But still the picture is not complete and therefore more research 
is needed to treat these therapeutic resistant diseases.  
 
 
1.2.5 Estrogens and angiogenesis 
The formation of new blood vessels, known as angiogenesis, is essential for many 
physiological processes like wound healing, female reproduction, and embryogenesis. 
However an imbalance in the growth of blood vessels contributes to the pathogenesis of 
numerous disorders, including cancer. Signals that trigger angiogenesis include 
metabolic stress (for example low oxygen or low pH), mechanical stress, 
immune/inflammatory response and genetic mutations. Small blood vessels consist of 
endothelial cells, whereas larger vessels also are surrounded by mural cells (pericytes 
and vascular smooth muscle cells (VSMCs)). ERα and ERβ are both expressed in 
endothelial cells and VSMCs [132, 133]. 
In contrast to normal vessels, tumour vessels are structurally and 
functionally abnormal. They are highly disorganized, having an uneven diameter, being 
repeatedly turned and bend, dilated, and having excessive branching and shunts. 
Tumour cells cannot grow or metastasise to another organ without blood vessels, 
therefore targeting angiogenesis is a promising therapy in cancer treatment. But without 
an efficient blood supply the delivery of anti-cancer drugs to the tumour will not be as 
effective. Agents blocking the VEGF pathway, such as Avastin, have shown good 
results in preclinical tumour models, however in clinical trials it has not prolonged 
overall survival [134]. 
Endothelial cells, stromal cells, blood cells, extracellular matrix and 
tumour cells all release both pro- and anti-angiogenic molecules. Basic fibroblast 
growth factor (bFGF) was the first angiogenic factor identified [135], followed by the 
identification of a large number of angiogenic factors such as vascular endothelial 
growth factor (VEGF), one of the most potent endothelial mitogens. VEGF induces 
rapid angiogenic responses, and is commonly overexpressed in breast cancers. Several 
studies have also found an inverse correlation between VEGF expression and overall 
survival in breast cancer, and that increased VEGF or VEGF receptor (VEGFR) is 
associated with resistance to endocrine therapy [136-138]. 
Estrogens have been shown to stimulate angiogenesis through different 
mechanisms, but primarily through the release of VEGF [139]. In nude mice implanted 
with MCF-7 human breast cancer cells, estrogens stimulated angiogenesis within 
developed tumours, whereas the anti-estrogen tamoxifen inhibited angiogenesis in the 
tumours [140]. Induced angiogenesis by bFGF or VEGF in the chick chorioallantoic 
membrane, was also inhibited by several ER antagonists, including 4-
hydroxytamoxifen, nafoxidene, clomiphene and ICI 182,780 [141, 142]. Furthermore, 
the ER antagonist ICI 182,780 inhibited estrogen-induced cell proliferation, migration 
and tube formation of endothelial cells [143-145]. The SERM tamoxifen has been 
shown to reduce microvessel density in primary breast carcinomas [146], thereby 
causing tumour regression. Interestingly, tamoxifen also reduces angiogenesis in ER 
negative tumours [147].  
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The role of the two ERs in the cardiovascular systems has been studied in 
various mouse models. In ERα knockout mice, loss of ERα prevented estrogen 
stimulated angiogenesis [148], supporting a role of ERα in mediating the primary 
vasculoprotective effects of estrogen. As concluded from studies of ERβ deficient mice, 
ERβ seems to have an essential role in regulation of vascular function and blood 
pressure [149]. However, ERs physiological relevance and precise role in the 
vasculature, mediating the biological effects of estrogen, are still incompletely 
understood and remain to be determined.  
 
 
1.3 CELL ADHESION 
 
1.3.1 Introduction to cell adhesion 
Cell adhesion is required for the survival of normal cells, providing the cell with an 
instrument to communicate with its surroundings. The interaction of cells with 
neighbouring cells and with the extracellular matrix (ECM) influences a variety of 
signalling events involved in many important cellular processes, such as survival, 
differentiation, mitogenesis, maintenance of three-dimensional structures and normal 
function of tissues. These mechanisms, in response to extracellular signals must be 
tightly controlled to maintain the integrity of multicellular organisms [150].  
Cell interaction with neighbouring cells and the extracellular environment 
is mediated by different classes of cell adhesion molecules (CAMs), including 
integrins, cadherins, and members of the immunoglobulin and selectin families. The 
formation of organized structures by CAMs permits an efficient flow of information in 
signalling pathways. The creation of new tissues and organs, wound closure, 
extravasation of immune cells, are a few examples of processes all dependent on cell 
adhesion, with defective function in CAMs being involved in the pathological 
development of many diseases, including cancer, cardiovascular disease, and immune 
disorders [150]. 
Focal complexes are small matrix adhesions seen within spreading or 
migrating cells and usually found in membrane protrusions of the cell. These adhesions 
are very dynamic structures and either turn over or mature into larger, more elongated 
structures, called focal contacts (or focal adhesions). Focal adhesions are found in 
resting cells with low motility and are usually the attachment points of actin stress 
fibers to the cell membrane. Interestingly, at intermediate levels of adhesiveness a 
maximum rate of cell migration occurs, since weakly attached cells cannot generate 
traction to move efficiently, and at too high levels of adhesiveness cells cannot break 
contacts and are therefore immobile [151]. 
 
 
1.3.2 Extracellular matrix 
A large part of tissue volume, besides cells, is filled by a network of proteins and 
polysaccharides, namely the ECM. The matrix is secreted, assembled and remodelled 
by surrounding cells, and is divided into two types; interstitial/stromal ECM, that 
surrounds the connective tissues, and basement membrane (BM), that is present at the 
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basolateral surface of different cell types in many tissues [152, 153].  The BM is 
composed mainly of laminin, collagen type IV, entactin/nidogen, and proteoglycans. 
Besides providing an organizational role of the cells in the tissues, the ECM also 
controls the behaviour of cells, deciding whether they will proliferate, stop growing, 
migrate, or undergo apoptosis. Disruption of cell adhesion to the ECM has deleterious 
effects on cell survival, leading to anoikis, a specific type of apoptosis [154]. The 
effects of the ECM on cells are mainly mediated by the integrins. 
 
 
1.3.3 Integrin family of cell adhesion receptors 
Integrins mediate attachment of cells to the ECM and take part in specialized cell-cell 
interactions. Integrins are cell adhesion receptors, transmitting both mechanical and 
chemical signals, regulating the polarity of cells, and organising and remodelling the 
cytoskeleton during adhesion and migration. In addition to their role in adhesion, 
migration, and invasion, integrins can also regulate proliferation, survival, and 
differentiation. The integrin family consists of 18 α-subunits and 8 β-subunits, together 
forming 24 different heterodimers. Each heterodimer is non-covalently linked and 
grouped into subgroups depending on ligand-binding properties and subunit 
composition. The structures of the α- and β-subunits are similar, consisting of a long 
extracellular domain, a single transmembrane spanning domain and a short, 
noncatalytic cytoplasmic domain. Some integrins are ubiquitously expressed, while 
others are expressed in a stage- or tissue-restricted manner [155].  
The name “integrin” was given to symbolise its importance in 
maintaining the integrity of the cytoskeletal-ECM linkage. Apart from binding to ECM 
components, some integrins mediate cell-cell adhesion by binding to cellular counter 
receptors on other cells. They can also bind soluble proteolytic fragments and a number 
of pathogens use them as an entry into the cell. Many integrins recognize specific 
motifs present in their cognate ligands; the most common motifs are Arg-Gly-Asp 
(RGD), and Leu-Asp-Val (LDV) [156]. Each heterodimer can bind one or several 
ligands, which sometimes overlap between each heterodimer (Fig. 4). For example, 
integrin α5β1 selectively binds fibronectin, whereas integrin αVβ3 binds a wide range 
of ECM molecules, including fibronectin, fibrinogen, von Willebrand factor, 
vitronectin, and also proteolysed forms of collagen and laminin. The affinity for the 
ligands can also vary depending on the cell type in which the integrins are expressed. 
Furthermore, the function of some integrins can be compensated by others, such as 
α6β1 by α3β1, whereas other integrins cannot be replaced and their absence may lead 
to embryonic or perinatal lethality [157, 158].  
Integrins are bi-directional signalling receptors involved in outside-in and 
inside-out signalling. Upon ligand binding integrins undergo conformational changes, 
clustering together into focal contacts where they associate with actin-binding proteins 
such as talin, vinculin, and paxillin. This links the integrins to the cytoskeleton, and 
results in recruitment of enzymes leading to outside-in signalling. Integrins signal 
mainly by activating focal adhesion kinase (FAK) and subsequently Src-family of 
kinases (SFKs), but also through the PI3K/Akt pathway. Another way in which 
integrins transmit outside-in signalling is through their ability to influence growth 
factor receptors such as EGFR, VEGF and fibroblast growth factor receptor (FGFR). 
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The inside-out signalling mainly acts to bring integrins into its active conformation, 
enabling the integrin to bind its ligand [159].  
Figure 4. Integrin heterodimers and some of their ligands. 
 
 
1.3.4 Integrins in cancer 
Deregulated integrin function contributes to the pathogenesis of many diseases 
including cancer. Even though neoplastic cells are much less dependent on ECM 
adhesions for their survival and proliferation [160], they still benefit from integrin 
signals during tumour initiation and progression. Integrin signalling contributes to 
diverse functions in the tumour cell including migration, invasion, proliferation, 
survival and tumour angiogenesis. When comparing integrin expression between 
normal and tumour tissue, expression levels of integrins can vary considerably, where 
expression of integrins that favour proliferation, survival, and migration are enhanced 
in the tumour. However, these changes in integrin expression are complex and depend 
on the tissue of origin, stage of progression and histological type of the tumour. 
Although cell-type dependent changes in integrin signalling make it impossible to 
assign each integrin as pro- or anti-tumourigenic, several studies have indicated that 
integrin α6β4 and αVβ3 are often upregulated in many cancers, whereas integrin α2β1 
and α5β1 often are downregulated.  
Integrin α6β4 is shown to be highly expressed in tumours with strong  
activation of the PI3K/Akt pathway, in cell lines with HER2 expression [161-165] and 
in tumours expressing high levels of HER3 [166]. The β4 integrin is also expressed in 
tumour blood vessels, and shown to promote tumour angiogenesis [167]. Expression of 
integrin β4 is linked to poor prognosis in breast cancer [168]. Integrin αVβ3 is 
associated with cell invasion and metastasis [169]. Integrin α2β1 is expressed at high 
levels in normal differentiated epithelial cells, including those of the normal breast, 
however, in adenocarcinomas of the breast its expression is decreased [170]. It has also 
been observed that re-expression of integrin α2β1 in poorly differentiated breast 
carcinoma cells reverts the malignant phenotype to a differentiated epithelial phenotype 
[171]. Integrin α5β1 has  been shown to reduce tumourigenesis [172].  
Integrins are also involved in regulating the activities of the matrix 
degrading enzymes, matrix metalloproteinases (MMPs). Cancer cells produce, secrete 
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and activate MMPs, with the disruption of the surrounding BM being a key marker of a 
tumours transition to an invasive carcinoma. MMPs are secreted as inactive zymogens 
(pro-MMPs), which require proteolytic activation by proteases at the extracellular 
space, allowing specific localized regulation of the activation of the soluble MMPs 
[173]. The active form of MMP-2 has been shown to be able to bind integrin αVβ3 on 
the surface of invasive cells [174], thereby localising proteolytic activity to the invasive 
front. Furthermore, integrin αVβ3 also cooperates with MMP-9 and thereby enhances 
the migratory potential of breast cancer cells, which could be inhibited by tissue 
inhibitors of MMPs [175]. In the invasive breast cancer cell line MDA-MB-231, 
blocking of integrin α3 subunit reduced MMP-9 activity and inhibited  migration and 
invasion [176]. 
 
 
 
1.3.5 Integrins and therapeutic opportunities 
In recent years, progress has been made towards targeting integrins in cancer, due to the 
fact that integrins have been shown to play a direct role in cancer progression, and since 
tumour resistance to cytotoxic therapies often involves complex cell-ECM and 
microenvironment interactions. Several monoclonal antibodies and small molecules 
interfering with the adhesive function of integrins have been developed to treat a 
variety of conditions such as thrombosis, inflammation and neoangiogenesis [177]. In 
recent years progress has been made towards targeting integrins in cancer. Two major 
targets involve: 
Integrin β4, due to its angiogenetic effects, upregulation in tumour cells 
and angiogenic endothelial cells, and enhancement of tyrosine kinase receptor 
signalling. Inactivation of integrin α6β4 is seen to inhibit tumour growth both in vitro 
and in vivo [178, 179].  
Integrin β1 is aberrantly expressed in approximately 30-50% of breast 
cancers and correlates with more poorly differentiated tumours, presence of axillary 
node metastasis, and a decrease in overall and recurrence-free survival [180-182]. 
Inhibition of integrin β1 with an inhibitory antibody has been shown to decrease 
proliferation and increase apoptosis of breast cancer cells, resulting in changes in the 
composition of tumour colonies, whereas non-malignant cells are unaffected. This was 
also seen in vivo, with no discernible toxicity to the animals making integrin β1 a 
promising therapeutic target and predictive factor [183]. In addition, emerging evidence 
indicates that integrin β1 has an important role in mediating resistance to cytotoxic 
chemotherapies [184-189]. Therefore it has been suggested that integrin β1 should be a 
prognostic marker to identify patients with high-risk disease, and who therefore may 
benefit from a more aggressive targeted therapy, such as radiation therapy.  
These studies highlight the importance of continued research in the role 
integrins have in tumour progression, the development of new agents as cancer 
therapeutics, and the identification of factors that influence their effectiveness. Integrins 
are also found in tumour-associated host cells, such as fibroblasts, bone marrow-
derived cells, vascular endothelium and platelets. Thus, integrin antagonists may also 
inhibit tumour progression both in the tumour cells themselves and in the tumour 
microenvironment. 
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1.3.6 E-cadherin 
Cadherins are the major CAMs responsible for calcium dependent cell-cell adhesion. 
The first three cadherins discovered were named accordingly to which tissue they were 
found in; E-cadherin in epithelial cells, N-cadherin on nerve cells, muscle and lens 
cells, and P cadherin on cells in the placenta and epidermis. E-cadherin is essential for 
epithelial cell shape and in maintenance of the epithelial phenotype. It is expressed 
ubiquitously by epithelial cells, and inhibition of its function leads to loss of the 
epithelial characteristics. E-cadherin also plays important roles in proliferation, 
survival, differentiation, and migration. Knockout of the gene results in embryonic 
lethality [190]. 
Cadherins share an extracellular domain consisting of multiple repeats of 
a cadherin-specific motif [191] and mediate calcium-dependent homotypic cell-cell 
adhesion at specialized sited called adherens junctions. Here they establish linkages 
with the actin-cytoskeleton through the catenins, α-, β-, γ-catenins, and p120. These 
catenins are essential for the function of E-cadherin, where deletion of the catenin 
binding sites leads to loss of cadherin mediated adhesion. Loss of membrane E-
cadherin results in free β-catenin which may enhance transcription of TCF/Lef-1 
regulated genes [192]. E-cadherin is trafficked to and from the cell surface by exocytic 
and multiple endocytic pathways and subsequently recycled to sites of new cell-cell 
contacts or sorted to the lysosome for degradation. 
 
 
1.3.7 E-cadherin in cancer 
In vitro and in vivo studies have implicated E-cadherin as both an 
invasion and tumour suppressor. Loss or mutation of E-cadherin, or disruption of 
cadherin-catenin complexes in tumours, are associated with an invasive malignant 
phenotype. In breast cancers, partial or total loss of E-cadherin correlates with loss of 
differentiation characteristics, increased tumour grade, metastatic behaviour and poor 
prognosis. Moreover, reduced E-cadherin expression is often associated with 
inappropriate expression of N-cadherin and cadherin-11, proteins usually expressed in 
mesenchymal cells. In mice, forced downregulation of E-cadherin promotes tumour 
invasion and metastasis [193], whereas, forced- or over-expression of E-cadherin 
results in inhibition of breast cancer growth, invasion and metastasis, both in vitro and 
in vivo [194, 195].  
About 80% of the mutations that have been identified in the E-cadherin 
gene result in a truncated protein, whereas the remaining 20% are missense mutations. 
Various mechanisms, both genetic and epigenetic, contribute to the disruption of E-
cadherin dependent junctions in cancer cells. Some carcinomas acquire loss-of-function 
mutations in the E-cadherin gene, whereas in others, members of the SNAIL/SLUG 
family of transcription factors suppress transcription of the E-cadherin gene. Even 
RTKs and SFKs can induce the disruption of adherens junctions in neoplastic cells 
containing E-cadherin expression [196, 197], where tyrosine phosphorylation of the E-
cadherin/β-catenin complex by RTKs results in ubiquitinylation and subsequent 
endocytosis and degradation. Hypermethylation around the promoter region of E-
cadherin is also a common silencing mechanism of the gene. Another mechanism 
involves cleavage by MMPs, which disrupts cadherin mediated cell-cell contacts.  
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One of the hallmarks for the transition from a benign tumour to a 
metastatic tumour is epithelial-mesenchymal transition (EMT). EMT is a process where 
epithelial cells lose their epithelial characteristics and acquire a mesenchymal-like 
phenotype. This change involves the loss of E-cadherin-mediated cell-cell adhesion, 
gain of expression of mesenchymal genes, loss of apical-basal polarity, acquisition of a 
more migratory phenotype and a reorganization of the cytoskeleton [197]. EMT has 
been described as an important process in tumour progression, metastatic processes and 
in therapeutic resistance. However, not all tumour types require EMT to initiate 
metastatic invasion [198]. Several environmental factors and signalling pathways have 
been described to induce EMT, including receptor tyrosine kinase receptors.  
 
 
1.4 RECEPTOR TYROSINE KINASES 
 
1.4.1 Epidermal growth factor receptor family  
Cell growth is tightly regulated through the activation of cellular signal transduction 
pathways, with growth factors and their receptors playing important roles in 
communication between the outside and inside of the cell. The human EGFR family 
consists of four closely related receptors: EGFR, HER2, HER3 and HER4, containing 
an extracellular ligand binding domain and an intracellular RTK domain. HER3, 
however, is different from the other members in that it has a deficient tyrosine kinase 
domain and therefore relies on heterodimerisation with other members of the EGFR 
family for transduction of its signals. These receptors activate numerous downstream 
pathways in response to extracellular ligands, resulting in effects on differentiation, 
migration, proliferation and survival. There are no conventional ligands for HER2, 
which instead acts as a dimerisation partner for the other members of the EGFR family, 
but the other receptors are each activated by binding a subset of EGF-related growth 
factors [199]. The EGFR family can also be activated through ligand-independent 
mechanisms such as irradiation and high receptor density due to overexpression [200, 
201]. Upon ligand binding, the receptors undergo a conformational change, form active 
homodimers or heterodimers, activate their intracellular kinase activity by 
autophosphorylation and associate with specific signalling molecules to subsequently 
initiate numerous downstream signalling events such as mitogen-activated protein 
kinase (MAPK) and Akt signalling pathways. The activated receptor is then 
internalised and either destroyed, attenuating the signal, or recycled to the outer 
membrane to be reactivated.  
 
 
1.4.2 EGFR family and cancer 
At least three of the four receptors, EGFR, HER2, and HER3 have important roles in 
human mammary carcinogenesis and resistance to endocrine therapy. In contrast to the 
other family members, HER4 seems to mediate anti-proliferative effects and does not 
appear to play a major role in cancer pathogenesis [202, 203]. Instead HER4 expression 
has been associated with favourable prognostic factors and a more positive outcome 
[204-207]. EGFR and HER2 are commonly amplified in breast cancer. Abnormal 
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receptor activation is due to several mechanisms including receptor overexpression, 
mutations and ligand-dependent and independent mechanisms. Each alteration leading 
to phosphorylation of the receptor and activation of downstream events such as MAPK 
and PI3K/Akt signalling.  
The HER2 gene is amplified in 20-30% of breast carcinomas contributing 
to a more aggressive disease, poor survival and resistance to tamoxifen [118, 208-210]. 
HER2 overexpressing breast cancers are more likely to be ER negative, and in tumours 
that express both EGFR and HER2, ER is absent or expressed at low levels, inversely 
correlated with EGFR and HER2 [120, 211]. Patients with breast tumours expressing 
high levels of HER2 and the ER co-activator SRC3 often develop resistance to 
tamoxifen [83], possibly as high levels of SRC3 in breast cancer cells have been shown 
to increase HER2 mRNA and protein upon tamoxifen treatment [212]. HER3 is also 
overexpressed in many breast tumours and associated with poor prognosis [204, 213, 
214]. HER3 has six consensus binding sites for p85 SH2 adapter subunit of PI3K, 
therefore having the unique ability to channel the signalling to the PI3K/Akt signalling 
pathway, thereby favouring tumour growth and progression [215]. In contrast, other 
studies have reported a positive prognostic value of HER3 receptor status, where its 
expression is correlated with positive ER and PR status and inversely associated with 
histological grade and longer disease free survival [216, 217]. 
The importance of the HER2/HER3 heterodimer has emerged, where co-
expression of HER2 and HER3 has been associated with decreased patient survival and 
associated with resistance to endocrine therapy and EGFR family tyrosine kinase 
inhibitors [104, 123, 218-220]. HER2 tumours usually also express HER3 [218] and 
downregulation of either HER3 or HER2 correlates with reduced phosphorylation of 
both HER2 and HER3 [122, 221]. In MCF-7 cells that overexpress of HER2, thereby 
are resistant to tamoxifen, downregulation of HER3 enhances tamoxifen-induced 
apoptosis [122]. The HER2/HER3 heterodimer is believed to be the most biologically 
active and pro-tumourigenic form of the EGFR family complexes [222, 223]. 
 
 
1.4.3 Targeting EGFR family proteins in cancer 
As evidence for a role of the EGFR family in breast cancer pathogenesis has increased, 
in recent years, significant efforts have been made to target these receptors for cancer 
treatment. The current successful approaches include antibodies that bind the 
extracellular domain of HER2 and EGFR, and small molecule tyrosine kinase 
inhibitors (TKIs) that inhibit their intracellular kinase activity.  
Monoclonal antibodies against HER2 and EGFR have shown great 
promise in cancer therapy. Trastuzumab is a monoclonal antibody that inhibits HER2 
signalling by binding to its extracellular domain [224]. When used in combination with 
chemotherapy, trastuzumab is effective in approximately 1/3 of the patients with HER2 
positive tumours [225]. Many patients with HER2 positive breast tumours fail to 
respond or develop resistance to trastuzumab, even when combined with chemotherapy 
[225]. Therefore an idea has emerged that tumours develop alternative mechanisms to 
activate the PI3K/Akt pathway, which most likely contributes to resistance, including 
loss of PTEN [226, 227], activation of insulin-like growth factor-1 receptor (IGF-IR) 
[228] and PI3KCA-activating mutations [226]. Resistance to HER2 targeted therapies 
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has also been implicated in HER3-PI3K axis dysregulation, where ligands of HER3 
rescue cells from the anti-proliferative effects of trastuzumab in vitro [229].  
TKIs, such as lapatinib, block the kinase domain of both HER2 and 
EGFR, but show only limited activity as single agents in the treatment of HER2 
overexpressing breast cancers [224, 230]. The activity of EGFR and HER2 is clearly 
repressed in tumours treated with TKIs [231]. However, it was shown that the 
downstream target Akt was not clearly inactivated. Recent studies also show that TKI 
effectively prevents  auto-phosphorylation of EGFR and HER2, but as the 
transphosphorylation of HER3 was only transiently suppressed, and thereby HER3 
escaped the inhibition of the TKIs [220]. Targeting HER3 may therefore enhance the 
efficacy of RTK inhibitors. This creates a challenge in drug therapy since in this 
situation HER3 is the principle mediator of resistance, and since HER3 cannot be a 
target for TKIs since it does not have catalytic kinase activity. A monoclonal antibody, 
pertuzumab, which inhibits the dimerisation of HER2/HER3 is currently undergoing a 
phase II clinical trial as a possible way to overcome this [232]. It may also be possible 
to target HER3 downstream targets, PI3K/Akt, thereby abrogate HER3 signalling and 
associated resistance.  
Endocrine resistance is often associated with enhanced expression of the 
EGFR family [166, 233, 234], as mentioned above in the chapter “Endocrine 
resistance”. With the importance of the EGFR family and ER as therapeutic targets in 
breast cancer, there is increased interest in interactions between estrogen antagonists 
and EGFR family, where the appropriate combination of endocrine therapy and signal 
transduction inhibitor is a new area of intensive clinical investigation. In light of this, 
combined therapy with both tamoxifen/AIs and trastuzumab has  been found to offer 
more clinical benefits than with tamoxifen/AI alone in ER and HER2 positive breast 
cancers [104, 235, 236].  
 
 
1.5 PI3K/AKT SIGNALLING 
 
1.5.1 Introduction to PI3K/Akt signalling 
The serine/threonine protein kinase Akt, also known as protein kinase B (PKB), is a 
downstream target for PI3K [237]. The PI3K family is involved in signalling 
transduction events downstream of cytokines, integrins and growth factors, and is 
involved in cellular processes such as cell proliferation, growth, motility, survival and 
angiogenesis (Fig. 5) [238]. PI3Ks are dimeric enzymes composed of a separate 
regulatory (p85) and a catalytic (p110) subunit. Upon activation, PI3K phosphorylates 
phosphatidylinositol 4,5 diphosphate (PIP2) to generate phosphatidylinositol 3,4,5 
triphosphate (PIP3), resulting in Akt and phosphoinositide-dependent kinase (PDK) 
translocation to the cell membrane. PDK and other kinases then phosphorylate Akt, 
leading to its activation and initiation of downstream signalling cascades. PIP3 levels 
are tightly regulated by the lipid phosphatase PTEN. 
Activation of Akt at the plasma membrane requires phosphorylation on at 
least two regulatory sites for its maximal activity. Initially it is phosphorylated at 
Thr308, however, additional phosphorylation at Ser473 is necessary for its full 
activation [239]. Once activated, Akt translocates to the cytoplasm and nucleus where it 
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phosphorylates a number of key substrates that promote cell survival, cell cycle 
progression and motility. 
Given the importance of the PI3K/Akt pathway in regulating apoptosis, 
proliferation and differentiation it is not surprising that inappropriate activation of this 
pathway results in tumourigenesis. 
 
 
 
Figure 5. Overview of the PI3K/Akt signalling pathway (not all involved components 
are shown). Growth: One of the best conserved functions of Akt is its role in promoting 
cell growth, the primary mechanism being through the activation of mTOR.  Apoptosis; 
Akt can promote growth factor mediated survival by several mechanisms. Akt can 
phosphorylate BAD, thereby inhibiting its pro-apoptotic function. Akt can also activate 
MDM2 and the subsequent downregulation of p53 results in inhibition of apoptosis. 
Proliferation; Akt is known to play a role in the cell cycle. Akt can phosphorylate p27, 
thereby preventing p27 localisation to the nucleus, and thus attenuates its cell-cycle 
inhibitory effects. Similar effects are also seen with p21. GSK3 targets cyclin D and c-
myc for proteasomal degradation. Phosphorylation and inhibition of GSK by Akt 
enhances the stability of these proteins involved in G1-to-S-phase cell cycle transition. 
Metabolism; Akt stimulates glucose uptake in response to insulin. Akt phosphorylates 
GSK3, thereby preventing GSK3 from phosphorylating and inhibiting its substrate 
glycogen synthase, thus stimulating glycogen synthesis. Angiogenesis; Akt plays 
important roles in angiogenesis. Akt activates endothelial nictric oxide synthase 
(eNOS). The release of NO produced by eNOS can stimulate vasodilation, vascular 
remodelling and angiogenesis. 
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1.5.2 PI3K/Akt signalling pathway in cancer 
The PI3K/Akt pathway is often dysregulated in human cancer. Many genomic 
alterations have been found to activate this pathway, which contributes to tumour 
progression, metastases and resistance to treatment [238]. 
 Akt deregulation in breast cancer is not due to changed protein levels but 
due to alterations in signals that control its activation status. Thus mice overexpressing 
Akt do not show increased tumour incidence, whereas expression of constitutively 
active versions of Akt leads to tumourigenesis [240]. Constitutively active Akt is found 
in many types of cancers and is an indication of worse prognosis in breast cancer 
patients [241, 242]. Akt has been shown to activate ERα by phosphorylation [15], 
thereby promoting tamoxifen resistance. Further, in MCF-7 cells constitutively active 
Akt leads to proliferation on low levels of estrogen and resistance to growth inhibitory 
effects of tamoxifen [124]. 
In addition to mutational activation of Akt itself, alterations in upstream 
signalling components, such as mutational activation of PI3K, loss of PTEN, and 
overexpression of growth factor receptors, have been observed leading to constitutively 
active Akt. Mutations of the PIK3CA gene, encoding the p110α catalytic subunit of 
PI3K, occur at significant frequency in several cancers, such as breast, ovarian and 
colon [243]. These activate Akt and induce oncogenic transformation in vitro and in 
vivo [244-246]. PI3K also regulates integrin dependent cell motility by adjusting 
integrin responses in both normal and cancerous tissues. In breast cancer cells, PI3K is 
activated upon integrin ligation, promoting formation of lamellae and invasion [162]. 
Moreover, the negative regulator of PI3K signalling and the tumour suppressor PTEN 
is commonly inactivated in numerous tumour types, resulting in constitutive 
upregulation of PI3K activity [247]. Due to these recent discoveries, interest in 
developing small molecule inhibitors of PI3K isoforms and their effectors have 
emerged [248]. These may provide a highly effective approach since this pathway is so 
frequently mutated in cancer. 
Strong activation of PI3K/Akt signalling has also been seen in tumour 
cells expressing high levels of α6β4 integrin, which has been implicated in tumour 
progression and invasion, and associated with HER2 [162-164, 249]. Inactivation of 
integrin α6β4 leads to reduced PI3K activity [178] and depletion of the integrin β4 
subunit causes reduction in HER3 and Akt phosphorylation [166]. Interestingly, no 
ERβ expression was found in those tumours expressing high HER3 and integrin β4 
levels. Furthermore, overexpression of HER2 is also linked to elevated Akt activities 
[250-252]. 
 
 
1.6 PTEN 
 
1.6.1 Introduction to PTEN 
The tumour suppressor PTEN is a lipid phosphatase that inhibits cellular proliferation, 
growth and survival by inactivating PI3K dependent signalling by dephosphorylating 
its product, PIP3, thereby negatively regulating Akt signalling. PTEN also possesses 
other biological functions independent of its lipid phosphatase activity, such as 
regulation of cell migration by dephosphorylating FAK [253]. As an important cellular 
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regulator, PTEN itself is subjected to careful regulation to ensure its proper function, 
since defects in PTEN regulation have profound impact on carcinogenesis.  
 PTEN has been reported to be modified in multiple ways, including 
phosphorylation [254, 255]. Most cellular PTEN appears to be maintained in a 
phosphorylated and inactive state, and its transient activation is mediated though 
dephosphorylation, probably through autodephosphorylation by its own protein 
phosphatase activity [256]. Phosphorylation of PTEN causes it to remain inactive in the 
cytosol with decreased catalytic activity, whereas dephosphorylation translocates PTEN 
to the plasma membrane. The unphosphorylated form is more unstable and subject to 
ubiquitin-mediated proteasomal degradation. However some sites of phosphorylation 
makes PTEN more prone to degradation [254]. 
PTEN can also be regulated transcriptionally, for instance PPARγ and 
p53 [257, 258] have been shown to upregulate PTEN transcription, whereas TGFβ 
[259], downregulates transcription. Furthermore, the microRNA miR-21, which is 
frequently upregulated in cancer [260, 261], has also been shown to repress PTEN 
[262]. 
 
 
 
1.6.2 PTEN function in breast cancer 
Loss of expression of PTEN is a common event in breast cancer. Reduced PTEN 
protein levels, due to promoter methylation, loss of heterozygosity and posttranslational 
modifications are found in 31%-48% of breast cancers. On the other hand, PTEN 
mutations, which results in total loss of PTEN function, are relatively uncommon in 
breast cancer (<5%) [263-265]. Patients with PTEN loss show poor disease outcome 
[264-267], and low expression of PTEN correlates with unresponsiveness to 
trastuzumab [227], tamoxifen [268], and gefitinib [269]. 
PTEN mediates its main tumour suppressive effects by 
dephosphorylating PIP3, thereby inhibiting Akt signalling. PTEN loss correlates with 
activation of Akt in tumour cell lines and its re-expression leads to downregulation of 
phosphorylated Akt [270-272]. Exogenous addition of PTEN suppresses growth of 
tumour cells [273-275], with knockdown of PTEN in ER positive breast cancer cell 
lines resulting in anti-estrogen resistance and hormone-independent growth [127]. 
In mice, a negligible decrease in PTEN expression is sufficient to 
promote cancer susceptibility, where 80% expression of normal levels of PTEN caused 
the development of a spectrum of tumours, with breast tumours occurring at the highest 
penetrance [276].  
These obvious biological effects caused by a modest change of PTEN 
expression levels emphasises that PTEN needs to be precisely controlled. The fact that 
PTEN is the only defined regulator of PI3K/Akt signalling defines why it is such a 
dominant tumour suppressor. 
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2 AIMS OF THE STUDY 
 
The overall aim of this thesis was to increase our understanding of the molecular and 
cellular mechanisms of estrogen signalling in progression of breast cancer focusing on 
the anti-tumourigenic effect of ERβ. Specifically, our objectives were:  
 
- To explore ERβ function in tumour growth, focusing on angiogenesis 
and growth factor expression (Paper I). 
 
- To study how estrogens affect cell-cell adhesion by focusing on ERβ 
regulation of E-cadherin (Paper II). 
 
- To analyse estrogen effects on integrin expression and the modulation 
of adhesive and migratory properties of breast cancer cells expressing 
ERα and ERβ (Paper III). 
 
- To investigate if ERβ can modulate pathways implicated in endocrine 
resistance development, including PI3K/Akt and HER2/HER3 
signaling, as well as PTEN expression. (Paper IV). 
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3 METHODOLOGICAL CONSIDERATIONS 
 
3.1 CELL LINES 
Immortalised cell lines derived from various tissues and species are useful tools in 
research and are important in vitro models in cancer research. Cell lines have numerous 
advantages, they are easy to handle, can be propagated infinitely, and exhibit a 
relatively high degree of homogeneity. Furthermore, cell lines can be grown as 
xenografts, allowing investigation of effects both in vitro and in vivo. However, due to 
their continual culturing, cell lines are prone to genotypic and phenotypic changes, 
therefore subpopulations may arise, which was highlighted by Osborne and colleagues 
[277] for MCF-7 cells. Therefore such caveats need to be considered when using cell 
lines, and one must consider if the cell lines used are valid models for breast cancer.  
Breast cancer is a heterogeneous disease, with diverse histopathological 
features, genetic and genomic variations, and clinical outcomes. Therefore no 
individual experimental model system fits all aspects of the disease. Most of the cell 
lines used in breast cancer research are derived from advanced-stage tumours, rather 
than primary lesions, and therefore represent the most malignant variants. Thus breast 
cancer research does not necessarily rely on the best representative cell lines. It would 
be more clinically relevant to use cells that are derived directly from primary tumours, 
especially since most drug therapies are directed against these. An alternative would be 
to use primary cultures derived directly from tumours. However there are 
disadvantages with primary cells; for instance, they grow slowly, have a finite lifespan, 
and often they only survive two or three passages. When large amounts of cells are 
needed this is a limitation. 
Cells grown in vitro are routinely cultured on a two-dimensional (2D) 
substratum, plastic, and most of the studies done so far have characterized proliferation, 
differentiation, survival, and molecular and biochemical pathways on 2D substrate. 
This is a huge limitation, since this environment differs markedly from the breast 
microenvironment. Cells in 2D lack exposure of components of the ECM, they do not 
recapitulate three-dimensional (3D) tissue architecture and lack heterotypic cell-cell 
interactions [278, 279]. Furthermore, in vivo acquired resistance to cytotoxic therapies 
often involves complex cell-ECM and microenvironment interactions. These 
interactions are not functional in a standard 2D tissue culture, with studies using 3-
dimensional cultures showing how these interactions significantly affect the tumour cell 
response to chemotherapy and radiation [280]. Altogether these aspects need to be 
considered. 
Considerations of limitations and disadvantages have been taken into 
account when designing experiments and interpreting results in cell lines used in this 
thesis. The following cell lines were used: 
 
- T47-D; human luminal epithelial ductal breast cancer cell line with high 
endogenous expression of ERα. These cells also express PR and are 
responsive to estrogen. T47D cells have a PIK3CA mutation (H1047R) 
in its catalytic domain [281]. T47-DERβ cells, expressing ERβ 
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(ERβ485), were obtained from Dr. Anders Ström. These cells are under 
the control of an inducible tet-off system.  
 
- MCF-7; human luminal epithelial ductal breast cancer cell line with 
high endogenous expression of ERα. These cells also express PR and 
are responsive to estrogen. MCF-7 cells also have a PIK3CA mutation 
(E545K) in its helical domain [281]. MCF-7ERβ cells, expressing ERβ 
(ERβ485), were obtained from Dr. Anders Ström. These cells are under 
the control of an inducible tet-off system. 
 
- HC11; undifferentiated mouse mammary epithelial cell line. These cells 
have stem cell properties and can be induced to differentiate, (through 
EGF removal and addition of lactogenic hormones), into different 
lineages according to hormonal conditions [282-285]. They can also 
grow on reconstituted basement membrane, such as Engelbreth-Holm-
Swarm (EHS), and form polarised acini. The formation of acini occurs 
through a period of ten days of active proliferation, followed by arrest 
and apoptosis to form the lumen [286]. This type of growth recapitulates 
mammary morphogenesis in vivo. 
 
 
3.2 XENOGRAFTS 
Cell lines can be grown as xenografts thus allowing investigation of the in vivo 
environment. However, there are some caveats to consider when using xenograft 
models. As mentioned above, the cell lines used may not represent the most common 
types of cancer observed in the clinic. Furthermore, xenografts must also be established 
in immunocompromised mice, thus the absence of an intact immune system may affect 
tumour development and progression [287]. The microenvironment may differ between 
human and mouse, depending on where the cells are injected/transplanted thereby 
altering the growth of the cells. However, it is still major benefit to grow the cells 
inside a host and in a three dimensional environment. 
 
 
3.3 REAL-TIME PCR ANALYSIS 
Real-time PCR analysis is a very sensitive method for quantification of mRNA. 
Conventional PCR uses endpoint measurements and relies on either the size or 
sequence of the amplicon. Whereas with real-time PCR, as the name implies, each 
transcript is detected in “real time”, making the quantitation easier and more precise. 
For real-time PCR, total RNA from tissues or cells was extracted and reversely 
transcribed into cDNA and analyzed using gene-specific primers. Compared to 
conventional PCR, smaller amounts of samples can be used to quantify mRNA. 
The method is based on the detection of fluorescence produced by a 
reporter molecule, DNA binding SYBR green or gene-specific TaqMan probes. 
TaqMan probes are sequence specific probes consisting of oligonucleotides that are 
labeled with a fluorescent reporter and a quencher moiety, which emits fluorescence 
upon hybridization to the right template. However, these probes are very expensive. 
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SYBR green, a non-specific fluorescent dye, binds to the minor groove of the DNA 
double helix, and emits fluorescence upon DNA binding. SYBR Green is a simple and 
cheap option for real-time PCR, but the drawback is that both specific and nonspecific 
products generate signals, since SYBR green will bind to all dsDNA products. 
Therefore the specificity of the primers must be thoroughly tested by melting curve 
analysis to confirm one single PCR product.  
SYBR Green based assays were used in the work described in this thesis, 
and melting curves have been made for each new primer pair. As reference gene 18S 
rRNA was used as an internal control for differences in input material. 
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4 RESULTS AND DISCUSSION 
 
4.1 ESTROGEN RECEPTOR β INHIBITS ANGIOGENESIS AND GROWTH 
OF T47D BREAST CANCER XENOGRAFTS (PAPER I) 
In the mammary gland, estrogens are potent mitogens, regulating the growth, 
development and function of normal as well as cancerous cells. ERα mediates the 
proliferative effect of estrogen in breast cancer, whereas ERβ seems to be anti-
proliferative. E2 treatment of ERα-positive T47-D and MCF-7 cells implanted into 
mice has been shown to increase proliferation and tumour growth [288, 289]. Since 
ERβ expression decreases or disappears during tumour development [290, 291], the 
question arised whether reintroduction of ERβ into ERα-positive breast cancer cells 
could influence  the tumour inhibitory properties.  
To investigate this hypothesis, T47-D breast cancer cells with inducible 
expression of ERβ (T47-DERβ) and normal T47-D cells, used as control, were 
implanted into the mammary fat pad of immunodeficient SCID/beige mice. Mice were 
also implanted with E2 containing pellets. At the endpoint of 30 days, tumour growth 
was reduced up to 80% in mice implanted with cells expressing ERβ, compared to the 
T47-D control cells. Further in three out of eight animals implanted with T47-DERβ 
cells, no tumour tissue could be found, indicating that regression was complete. 
Furthermore, the Ki67 proliferation index was decreased in the ERβ expressing 
tumours, with Ki67 inversely associated with ERβ expression at all time points 
measured. These results clearly showed that expression of ERβ in T47-D breast cancer 
xenografts reduced tumour volume, giving further support to the notion that ERβ is 
anti-proliferative. 
For successful tumour growth, increased proliferation must be 
accompanied by supply of oxygen and nutrients provided by increased blood supply. 
This is achieved by increased angiogenesis and blood microvessel density [292-294]. 
Increased microvessel density is a strong predictor for aggressive disease. Microvessel 
density was examined in the tumours by visualising endothelial cells with an antibody 
against CD31. Interestingly, ERβ expression correlated with reduced microvessel 
density, suggesting that ERβ may influence angiogenesis in tumours. However, since 
oxygen tension is a major stimulator of angiogenesis, it was also possible that the lower 
microvessel density in the ERβ expressing tumours was simply due to reduced tumour 
volume and thereby less hypoxic milieu. 
To address this question, levels of VEGF and PDGFβ growth factors, 
important for regulating angiogenesis, were investigated in the xenografts. Both 
PDGFβ protein and mRNA levels were reduced in the ERβ expressing tumours. No 
reduction of VEGF mRNA levels was seen, whereas VEGF protein showed a 
nonsignificant trend to be decreased in the ERβ expressing tumours. Based on these 
findings, we concluded that the tumour suppressive effects of ERβ in vivo, are most 
likely a consequence of the combined action of reduced angiogenesis and proliferation. 
Still, induction of these growth factors may be due to hypoxic conditions independent 
of ERβ. 
To investigate if ERβ or hypoxia were involved in regulating the 
production of VEGF and PDGFβ, T47-DERβ cells were incubated in normoxic and 
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hypoxic conditions in vitro. In both conditions, VEGF and PDGFβ mRNA and secreted 
protein were reduced upon ERβ expression. To further investigate a possible 
transcriptional regulation, T47-D cells were transiently transfected with promoter 
constructs of VEGF and PDGFβ. It has earlier been reported that ERα increases 
expression of PDGFβ and VEGF, and as expected, estrogen treatment increased VEGF 
and PDGFβ promoter activity, whereas co-transfection with an ERβ expression vector 
together with estrogen decreased both VEGF and PDGFβ promoter activities. 
Accordingly, ERβ might be a transcriptional inhibitor of VEGF and PDGFβ, opposing 
the effect of ERα. However more detailed studies are needed to confirm this regulation.  
There was only a minor upregulation of VEGF promoter activity in 
response to E2. However, earlier studies have reported that longer constructs show 
strong activation by estrogen [295].  Buteau-Lozano also showed that deletion of 1.2-
2.3 kb upstream of the transcription start site in the VEGF promoter abrogates E2-
dependent transcription. This may give an explanation to our lower response to E2, as 
our promoter construct did not contain this upstream sequence.  
Reduction of growth factor expression and secretion could provide one 
explanation as to how ERβ inhibits tumour growth, since besides being pro-angiogenic, 
PDGF family members also stimulate proliferative and invasive properties of cancer 
cells [296, 297]. Furthermore, besides activating endothelial cells, which results in 
proliferation and migration, VEGF also influences breast cancer cell survival and 
growth through direct effects on cancer cell surface receptor VEGFR-2 in an autocrine 
fashion [298]. 
The main targets for angiogenic factors are the endothelial cells. 
Estrogens have been shown to be important for angiogenesis and can also affect 
endothelial cells directly. Endothelial cells express both ERα and ERβ. ERα has been 
shown to stimulate VEGFR-2 expression of endothelial cells, resulting in increased 
sensitivity for VEGF, whereas endothelial cells only expressing ERβ do not increase 
proliferation upon E2 treatment [144, 299, 300]. In MCF-7 xenografts, estrogen was 
shown to stimulate angiogenesis, whereas tamoxifen inhibited endothelium growth 
[140]. Tamoxifen has also been shown to reduce vascular density within a tumour 
[146].  
The immune system has been shown to play important roles in the 
prevention and repression of cancer. As this study used immunodeficient mice, a 
complete picture of the possible anti-tumourigenic effects of ERβ cannot be obtained 
due to the lack of functional lymphocytes. 
Altogether these results show the importance of ERβ in the 
tumourigenesis of breast cancer, further supporting its anti-proliferative role, and also 
highlight a possible role in regulating angiogenesis. This makes ERβ an interesting 
clinical target, used in combination with both anti-proliferative and anti-angiogenic 
therapies. 
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4.2 DIFFERENT ROLES OF ESTROGEN RECEPTORS α AND β IN THE 
REGULATION OF E-CADHERIN PROTEIN LEVELS IN A MOUSE 
MAMMARY EPITHELIAL CELL LINE (PAPER II) 
Studies in ERβ knockout mice have shown reduced expression of several adhesion 
proteins in the lactating mammary gland, including E-cadherin [65]. Furthermore, E-
cadherin mRNA in the mouse ovary has been shown to be upregulated by E2 
administration [301]. Previously it has also been shown that ERβ opposes ERα induced 
proliferation, and that its expression increases apoptosis whereas its inactivation results 
in loss of growth contact inhibition [73]. This suggests an important role for ERβ in 
tumourigenesis, as it seems to have an important role in regulating cell-cell adhesion. 
However, the mechanisms behind this regulation remain to be elucidated. Therefore the 
focus of this study was to elucidate ERβs role in cell-cell adhesion, with a focus on E-
cadherin. 
To address the question above we used HC11 mammary epithelial cells 
with stable expression of short inhibitory hairpin RNAs (shRNA) towards ERα or ERβ 
(siERα and siERβ, respectively). Using the siRNA approach, we could see that E-
cadherin protein levels were upregulated in response to E2 or DPN in ERβ expressing 
cells. No effect was seen with the ERα agonist PPT in these cells. Furthermore, E-
cadherin protein levels were downregulated in response to PPT or E2 only when ERβ 
expression was reduced. The observed effects could be reversed by the anti-estrogen 
ICI. These effects were specific for E-cadherin, since β-catenin, α-catenin and p120 
catenin did not show any differential regulation by E2 treatment. All together, this data 
suggests that ligand activation of ERβ upregulates E-cadherin levels and protects it 
from ERα-induced downregulation, whereas ligand activation of ERα in the absence of 
ERβ downregulates E-cadherin levels. This suggests that the different ratios of 
ERα/ERβ are important in the regulation of E-cadherin in ER positive cells. 
E-cadherin has been shown to be regulated by estrogens [302-304]. In 
MCF-7 breast cancer cells, ERα has been correlated with increased E-cadherin 
expression by upregulation of the Snail/Slug inhibitor, MTA3 [302], however, no 
correlation was seen with MTA3 and E-cadherin expression in our HC11 cells. This 
indicated that in these cells, E2 regulation of E-cadherin did not involve the MTA3 
pathway. Others have also shown in MCF-7 cells that ERα directly regulates E-
cadherin by binding to the E-cadherin promoter with associated co-repressors, resulting 
in repression of E-cadherin expression [304]. Using real-time PCR, mRNA levels of E-
cadherin were measured at different time points in the HC11 cells. Treatment of cells 
with DPN, E2 or PPT induced a slight increase in E-cadherin mRNA after 2 hours. To 
study if the slight mRNA induction was translated into increased protein levels, 
immunoblots were performed at 3 and 6 hours incubation with respective ligands, but 
no significant tendencies were observed at the protein level. At the same time, reporter 
assay was performed with candidate regulatory elements (AP1 and 2 putative EREs) 
from the E-cadherin gene. No ER-mediated activation of transcription was found. This 
suggests that in HC11 cells, ER regulation of E-cadherin protein levels cannot be 
explained by changes in gene expression or MTA3 levels, instead it seems that the 
opposing activities of the ERs occur posttranscriptionally. It is noteworthy to mention 
that MCF-7 cells do not express ERβ, which may explain the discrepancies between 
our studies and the studies with MCF-7 cells. Furthermore, since Fujita et al [302] used 
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10% FBS instead of E2 to stimulate cells, it is not clear whether the effect seen by them 
was through ligand-dependent or independent activation of ERα. On the other hand, in 
ERβ positive, ERα and AR negative DU145 prostate cancer cells, E-cadherin levels are 
increased upon ligand activation of ERβ [303], consistent with our results.  
Regulation of E-cadherin expression can occur at several levels from 
gene methylation [305, 306], transcriptional repression (as mentioned above), to 
external shedding by MMPs [307-309]. To further investigate the possible mechanisms 
behind E2 induced downregulation of E-cadherin protein levels in siERβ cells, 
extracellular shedding was investigated. Immunoblotting was used to analyse E-
cadherin fragments in the conditioned media. An 88 kDa E-cadherin protein fragment 
was seen at higher levels in E2 stimulated siERβ cells. This was further confirmed by 
immunofluorescence, where less membrane staining and more cytoplasmic staining 
was observed. These results suggest that one possible mechanism of how E-cadherin is 
downregulated by ERα in the absence of ERβ is through E2/ERα-induced shedding. 
Furthermore, the increase in E-cadherin fragments may also inhibit cell adhesion in a 
paracrine way [310, 311]. Unfortunately, we were not successful in identifying the 
MMPs associated with this increase in shedding. In addition, immunofluorescence 
stainings of cell-cell contacts in siERβ cells showed less attachment and increased 
cytoplasmic granular patterns in siERβ cells. These cells were also larger and flatter 
than the controls. However, ICI did not reverse the effect seen in the siERβ cells, 
indicating that the observations are not ERα mediated, but instead a result of reduced 
levels of ERβ. In summary, these results show that loss of ERβ induces differential E-
cadherin cellular localization. 
E-cadherin levels can be modulated at the cell surface by endocytosis, 
endosomal sorting and lysosomal degradation. To further investigate if the E-cadherin 
granular cytoplasmic staining was related to internalisation, biotinylated (extracellular) 
protein was investigated. Internalised biotinylated proteins were seen in siERβ cells, 
whereas in the wild type (wt) or control-siRNA HC11 cells the staining was still 
associated with the cell membrane. However this internalisation was not further 
enhanced by E2. Since the fate of the internalised protein can be towards recycling or 
degradation we decided to further study if E2 could influence the fate of the 
internalised E-cadherin. 
Clathrin-dependent and clathrin independent mechanisms have been 
postulated for E-cadherin internalisation, therefore double immunofluorescence 
stainings with clathrin and E-cadherin antibodies were performed in E2-treated and 
untreated si-ERβ cells. The overall co-localisation was higher in E2 treated siERβ cells 
than in untreated cells. To further investigate the fate of the intracellular granules 
observed in siERβ cells, cells were stained with markers for early endosomes (Rab5), 
late endosomes (Rab7), recycling vesicles (Rab4), exocytic vesicles (Rab11), and 
lysosomal vesicles (LAMP-1). E-cadherin partially co-localised with early endosomes 
and lysosomal vesicles, which was further enhanced by E2. All together, E2 induces E-
cadherin internalisation through clathrin-dependent pathway. This suggests that when 
ERβ levels are low, ERα induces shedding and influences E-cadherin fate towards 
degradation in the lysosome.  
Another possible mechanism is the caveolin-1-mediated endocytosis of 
E-cadherin. Co-localisation studies showed that in siERβ cells, E-cadherin positive 
granules co-localised with caveolin. However this co-localisation was not enhanced by 
E2 treatment, suggesting another mechanism of internalisation of E-cadherin upon loss 
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of ERβ. To further confirm this, a disruptor of caveolae, nystatin, was used to see if E-
cadherin could be restored in the siERβ cells. Nystatin partially restored membrane E-
cadherin under basal conditions but not in E2 treated siERβ cells, suggesting that the 
downregulation of E-cadherin protein levels induced by E2/ERα happens 
independently of the formation of caveolae and is instead related to extracellular 
shedding and lysosomal degradation.  
Ubiquitination of E-cadherin leads to destabilization of adherens 
junctions, internalisation and further degradation [312]. Ubiquitin mediated 
internalisation is generally associated with lysosomal degradation [313], however some 
reports show that the proteasome also might be involved in this regulation [314, 315].  
An increase in E-cadherin membrane localisation was seen when treating the siERβ 
cells with two different proteasome inhibitors, however E-cadherin protein levels were 
not affected. Taken together, these observations indicate that inhibition of the 
proteasome favours membrane localisation, but as it does not prevent E2 induced 
decrease of E-cadherin levels, E2-induced shedding is not influenced. One possibility is 
that proteasome inhibition depletes the cells from free pools of ubiquitin [316], leading 
to a shorter fragment of E-cadherin in the membrane. The role of the proteasome in this 
system remains to be studied. 
Loss of E-cadherin is also associated with activation of beta-catenin, 
transactivation of invasion-associated genes and acquisition of a migratory phenotype, 
all characteristics of EMT. To further support our data we found that loss of ERβ was 
associated with an E2-induced activation of β-catenin reporter activity, resulting in 
increased cellular proliferation [73]. An increase of migration in wt cells was also seen 
in cells treated with PPT, suggesting that ERα may increase the migratory potential of 
cells. However the expression of mesenchymal markers was not increased in response 
to loss of ERβ. Thus the phenotypic changes seen in siERβ cells did not correlate with 
these EMT characteristics. 
Finally, E-cadherin is a significant player in the formation of adherens 
junctions and necessary for maintaining cell polarity. Growth of siERβ cells on 
reconstituted basement membrane was disorganized, as the cells did not arrest but 
instead continued growing, thus giving origin to larger structures. This suggests that 
ERs regulation of E-cadherin cellular localization and increased β-catenin 
transcriptional activity might be related to these effects. 
In summary, these results show the importance of ERβ in regulating cell-
cell adhesion and in maintaining the differentiated phenotype of the cell.   
 
 
4.3 EXPRESSION OF ESTROGEN RECEPTOR β INCREASES INTEGRIN 
α1 AND INTEGRIN β1 LEVELS AND ENHANCES ADHESION OF 
BREAST CANCER CELLS (PAPER III)  
Cell migration plays an important role in many pathological and biological processes, 
including cancer, leading to invasion and metastasis, which in turn promotes the spread 
of tumours, thereby leading to mortality. Integrins, cell surface receptors for the ECM, 
play key roles in the regulation of normal and tumour cell migration and survival. 
Interestingly, integrins undergo dramatic alterations in their levels of expression and 
affinity when comparing preneoplastic tumours with invasive tumours. Earlier studies 
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have indicated that estrogens can affect integrin expression [317, 318]. Since previous 
results in mice and cell lines suggest a role for ERβ in regulating cell adhesion [65, 
319] as well as being associated with less invasive tumours [320], and inhibiting the 
invasion of breast cancer cells [74], we aimed to investigate the function of ERβ in cell-
ECM adhesion and migration in breast cancer cells. 
To investigate this, we used ERα positive T47-D breast cancer cells with 
inducible expression of ERβ and screened for ERβ regulation of different integrin alpha 
subunits (α1, α 2, α 3, α 4, α 5, α V, and α Vβ3) and beta subunits (β1, β2, β3, β4, β6, α 
Vβ5, and α 5β1) using an ELISA-based method. An upregulation of integrin α1 and 
integrin β1 was found, which was confirmed by FACS. This upregulation was further 
enhanced by the treatment with the ERβ agonist DPN, and repressed by the antagonist 
ICI. Since integrin α1 only exists as a heterodimer with integrin β1, these results 
indicated that expression of ERβ resulted in a specific increase of the cell surface ECM 
receptor integrin α1β1. 
Next, the regulatory mechanisms behind the increase in integrin α1 and 
β1 were investigated. Using quantitative real-time PCR, we showed that integrin α1 
mRNA was upregulated upon ERβ expression and partially reversed upon co-
incubation with the antagonist ICI, whereas integrin β1 mRNA was unaffected. To 
determine that this was not a cell specific effect, these results were confirmed in a 
second breast cancer cell line with inducible expression of ERβ, MCF-7ERβ, as well in 
SW480 colon cancer cells with constitutive expression of ERβ. These results altogether 
indicated that ERβ regulates integrin α1 at the mRNA level. Screening of the integrin 
α1 promoter region spanning 10kb revealed one ERE, one SP1 and six AP1 sites, 
which could be possible sites for ER regulation. Whether ERβ itself affects any of these 
regulatory elements or acts by inhibiting ERα repressive function on AP-1 sites remains 
to be studied. However, since ICI treatment, which downregulates ERα, decreased 
integrin α1 mRNA levels, this suggests that the upregulation is most likely to be 
achieved by ERβ. 
To further corroborate ERβ induction of integrin α1β1, total protein levels 
were also analysed by immunoblot or immunofluorescence. Both integrin α1 and 
integrin β1 protein levels were increased upon ERβ expression, thereby confirming the 
FACS data. Since integrin β1 mRNA was not increased upon ERβ expression, we 
assume that integrin β1 becomes stabilised upon heterodimerisation with integrin α1 
and accumulates, since integrin α1 only heterodimerises with integrin β1. It is also 
possible that ERβ affects other pathways, such as proteins that bind to the intracellular 
domain of integrin β1 and thereby activates and stabilises integrin β1. In both cases 
integrin β1 is less prone to degradation. 
Since integrins are essential for cells to adhere we further investigated 
adhesion and formation of adhesion complexes. ERβ expression caused a four-fold 
increase in number of adhesions detected per cell, as well as enhanced the integrin-
clustering density. Furthermore, ERβ also induced the formation of vinculin-containing 
focal complexes and actin filaments, all together suggesting a more adhesive potential 
of these cells. This was confirmed in an adhesion assay to different matrix proteins, 
namely collagen type I, collagen type IV, fibronectin, laminin, and vitronectin, where 
the expression of ERβ enhanced the adhesive potential to all different matrix proteins. 
Similar results were also observed in MCF-7ERβ and HT29ERβ cells. In addition to 
integrins α1 and β1, ERβ may also influence expression and activation of other 
integrins and proteins involved in the formation of adhesion complexes and thereby 
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influence adhesion to ECM. Adhesion to fibronectin and vitronectin increased upon 
ERβ expression, none of which is a ligand for integrin α1β1. This indicates that ERβ 
could have an effect on early signalling events involved in cell adhesion. Interestingly 
PRA usually predominates in breast cancer and in T47-D cells; an increase in 
PRA/PRB ratios (due to increased expression of PRA) to levels higher than 4:1, results 
in decreased adhesion and focal contact formation [321]. We observed upon ERβ 
expression a decrease in PRA/PRB ratios of 25% and therefore, some long-term effects 
of ERβ expression such as increased integrin β1 levels and increased adhesive 
potential, may be the result of changes in PR isoform ratio as well. However we did not 
incubate with progestins as was done in the study referred to above. Furthermore, the 
idea that the relative ratio of ERα/ERβ in cells dictates the response to estrogens, 
indicates that some effects we have observed may be influenced by this parameter, 
since we found that ERβ expression negatively influenced the ERα levels. 
The rate of cell migration is determined by the level of adhesiveness of 
the cells to their substrates. In view of ERβ-induced changes in integrin expression, 
formation of adhesion complexes and effects on cell-ECM adhesion, we examined 
influence of ERβ on migration. The migratory capacity of the cells was clearly reduced 
upon ERβ expression as seen with a wound assay and a chemotactic assay, which is in 
agreement with previous observations. 
In conclusion, these results indicate that ERβ affects integrin expression and 
clustering and consequently modulates adhesion and migration of breast cancer cells. 
Thus, ERβ may be a potential target in future therapies, where its expression and/or 
activation could stop or prevent the invasion and migration of breast cancer cells. 
 
 
4.4 ESTROGEN RECEPTOR β REPRESSES AKT SIGNALING IN 
BREAST CANCER CELLS VIA DOWNREGULATION OF HER2/HER3 
AND UPREGULATION OF PTEN – IMPLICATIONS FOR TAMOXIFEN 
SENSITIVITY (PAPER IV) 
Dysregulation of the cell cycle and the apoptotic pathway are fundamental events in 
cancer development. The effect of ERβ expression on cell proliferation has been widely 
studied and shown to be related to regulation of cell cycle proteins and apoptosis. 
However, ERβ effects on survival pathways like PI3K/Akt have not been extensively 
investigated. Therefore we were interested to investigate if ERβ expression had any 
effects on RTKs/Akt signalling, and as this pathway also is involved in regulating 
sensitivity to tamoxifen, if ERβ therefore could represent a putative player in regulating 
tamoxifen sensitivity. 
 The PI3K/Akt pathway plays important roles in regulating cell 
proliferation, growth, apoptosis and motility, and deregulation of this pathway is 
frequently seen in breast cancer, resulting in tumour progression, metastases and 
resistance to endocrine therapy [238, 241, 322, 323]. To investigate ERβ effect on Akt 
signalling, ERα positive T47-D and MCF-7 cells with inducible expression of ERβ 
were used. Upon 4 days of ERβ expression, levels of phospho-Akt (Ser473) were 
clearly downregulated in both cell lines. Total Akt levels remained unchanged, 
indicating that reduced phospho-Akt levels were due to less phosphorylation. No 
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changes in the mock cell line were seen, indicating that the changes in phospho-Akt 
were not due to changes in doxycycline concentration, but to ERβ expression. Also a 
downstream target of phospho-Akt, phospho-GSK3β (Ser9), was downregulated. 
Treatment with ER antagonists, ICI and tamoxifen, did not prevent ERβ-induced 
decrease of Akt phosphorylation. In summary, expression of ERβ in two different ERα 
positive breast cancer cell lines, clearly reduced activation of the Akt signalling 
pathway. 
 Receptors belonging to EGFR family are known for their role in breast 
tumour initiation and progression and for the development of endocrine resistance. 
Members of the EGFR family are also known activators of the PI3K/Akt pathway, 
therefore effect of ERβ on expression of EGFR, HER2 and HER3 was investigated. 
Levels of EGFR remained unchanged upon ERβ expression, whereas HER2 protein 
levels became upregulated and HER3 protein levels downregulated in both T47DERβ 
and MCF-7ERβ cells. This also correlated with changes at the mRNA level where ERβ 
expression upregulated HER2 mRNA and downregulated HER3 mRNA. ICI treatment 
increased both mRNA and protein levels of HER3, but did not inhibit ERβ-induced 
downregulation of HER3. However, with tamoxifen, there was a distinct difference 
between protein and mRNA levels, where tamoxifen abolished ERβ downregulatory 
effect at the mRNA level, which was not seen at the protein level. Interestingly, both 
antagonists ICI and tamoxifen increased HER2 protein and mRNA levels and abolished 
ERβ upregulation of HER2 protein levels, whereas mRNA was decreased. This was not 
clearly related to HER2 protein levels at 4 days, but at 7 days of ERβ expression. Since 
ERα has been shown to act as a transcriptional repressor of HER2 mRNA [212], we 
speculate that this change is due to the relative ERα/ERβ ratios in the cells, where upon 
heterodimerisation of ERα/ERβ, ERα homodimer-mediated repression of HER2 is 
relieved. Furthermore, in our cell systems, we have seen that ERβ reduces ERα levels, 
which provides another explanation of less ERα homodimer-mediated repression of 
HER2. In the light of these results, we also postulate that ERβ homodimers mediate 
HER2 repression, since removal of ERα makes ERβ act like a repressor not an 
activator.  
 HER3 activation results in strong activation of the PI3K/Akt signalling 
pathway, therefore we investigated if ERβ expression could decrease active 
HER2/HER3 and Akt. Addition of the HER3 ligand HRG-β1 clearly induced active 
HER2/HER3 and Akt, an activation that ERβ expression was able to reduce. This 
suggests that ERβ downregulates the PI3K/Akt pathway through decreased expression 
of active HER2/HER3. Since HER2 and HER3 have been linked to endocrine 
resistance, these findings suggest that ERβ agonists together with ERα and RTK 
inhibitors could be an approach to overcome endocrine resistance. 
 PTEN is a known downregulator of the PI3K/Akt pathway and its 
expression is often lost in tumours and associated with endocrine resistance. We thus 
found it important to investigate if ERβ had any effect on PTEN expression. PTEN 
mRNA and protein levels were clearly increased upon ERβ expression, further 
suggesting another possible mechanism of how ERβ could regulate Akt signalling.  
Both downregulation of PTEN, increased HER2/HER3 and Akt 
signalling, have all been associated with endocrine resistance in breast tumours. 
Furthermore, ERβ has been implicated as an indicator of endocrine response, where 
low expression is found in tamoxifen resistant tumours, and high levels are associated 
with a better clinical outcome [111, 115, 324, 325]. With our above described results in 
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mind we investigated if ERβ expression would sensitise MCF-7 and T47-D cells to 
tamoxifen. ERβ increased the sensitivity of both MCF-7 and T47-D cells to tamoxifen, 
thereby providing a mechanistic insight into how ERβ may contribute to endocrine 
sensitivity. Current endocrine therapies in breast tumours aim to impair ERα activity. 
Our results show that introduction of ERβ detection may allow a more precise selection 
of patients that will benefit from endocrine therapy. Furthermore, ERβ also seems to be 
a useful target in breast cancer by enhancing endocrine sensitivity. 
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5 CONCLUDING REMARKS AND FUTURE 
PERSPECTIVES 
 
Approximately fifteen years after its identification, dramatic progress has been made in 
defining the function of ERβ. The availability of knockout mice and the development 
of ERβ selective agonists have revealed its importance in physiological processes, 
diseases and signalling pathways. However, we still have a long way to go before we 
fully understand its multiple roles.  
In this thesis the aim was to gain more insight into the molecular and 
cellular mechanisms of estrogen signalling in breast cancer, focusing on the anti-
tumourigenic effects of ERβ in the breast. Several studies have reported that during 
tumour development in the breast epithelium, the expression of ERα increases, whereas 
that of ERβ decreases. The clinical significance of ERβ in breast cancer is still under 
debate, but the studies in this thesis have provided some insights into the functional role 
of ERβ in breast cancer and its possible role in defining clinical outcome. Although the 
mechanisms have not yet been fully characterised, ERβ seems to have several 
important inhibitory functions in breast cancer, such as affecting growth, adhesion, 
angiogenesis and sensitivity to endocrine therapy.  
In the 1970s, Folkman started the era of tumour angiogenesis, which 
today is one of the most intensively studied areas in cancer research, with several anti-
angiogenic drugs developed. In paper I we found that ERβ not only inhibited growth 
of tumour xenografts, but might also have a role in anti-angiogenesis by reducing 
expression of pro-angiogenic factors, which could have important medical implications. 
These results are intriguing; however, since the mice used are immunodeficient the 
complete picture of ERβ in angiogenesis is unclear. It would be interesting to see what 
effects the different ER selective ligands and antagonists would have on tumour growth 
and angiogenesis in vivo, as well as to look at anti-angiogenic factors and other possible 
targets such as those reported in papers II-IV. Furthermore, whether ERβ directly or 
indirectly influences angiogenesis through crosstalks with other signalling pathways 
needs to be investigated. The PI3K/Akt pathway is also activated by VEGF in 
endothelial cells, and since Akt can activate eNOS leading to angiogenesis, 
downregulation of Akt signalling by ERβ expression, seen in paper IV, could also be 
one explanation for these results. It is also possible that ERβ directly influences 
endothelial cells since these cells express both ERs. ERβ ligands used in combination 
with both anti-proliferative and anti-angiogenic therapies may increase the efficacy of 
these targeted therapies, however, ERβ physiological relevance and precise role in the 
vasculature is still incompletely understood and remains to be determined. 
Inactivation of E-cadherin is important in the progression of sporadic 
breast cancer, where its loss is a hallmark of the transition from a normal epithelium to 
poorly differentiated carcinoma. In paper II, we found that ERβ was important for 
maintaining cell-cell adhesion and for the differentiated phenotype - through E-
cadherin. However, the process seems complex; some effects were ligand independent, 
as well as depended on the relative ratio of ERβ/ERα. There also seemed to be a cell 
type specific regulation, since different reports have shown different regulatory 
mechanisms of E-cadherin. It would also be interesting to test these cells with 
knockdown of ERα or ERβ in vivo. Furthermore, the proteolytic enzymes responsible 
 37 
 
for fragmentation of E-cadherin need to be identified. Interestingly, integrins are 
involved in regulating MMPs, and in paper III we found changes of integrin 
expression upon ERβ expression, thereby providing a possible pathway for the 
fragmentation of E-cadherin.  
Few studies have addressed estrogen effects on integrin expression in 
breast cancer cells. In paper III we found that ERβ affects integrin expression, and 
increases the adhesiveness and decreases the migratory potential of breast cancer cells. 
Since changes in adhesion between cancer cells and ECM cause progression of 
metastasis, these results further strengthen ERβ anti-tumourigenic effects. However, 
ERβ can affect other pathways and proteins involved in cell adhesion and migration. As 
shown in paper II, loss of E-cadherin also correlated with increased cell migration. 
Therefore a full screen of all integrins, as well as adhesion related proteins needs to be 
completed to obtain the full picture of ERβ function in cell-ECM adhesion.  
Resistance to endocrine therapy remains a major problem. The effects of 
therapies and the resistance that arises clearly show and reflect the complex biology of 
the cell. The knowledge of the molecular mechanisms behind resistance to each 
endocrine agent is crucial, as well as the knowledge of mechanisms that would increase 
the sensitivity to endocrine therapy. It is interesting to note that in paper IV we found 
that the presence of ERβ increased the response to tamoxifen in two ERα positive cell 
lines, which is in concordance with clinical studies where ERβ seems to be a marker for 
endocrine sensitivity. One interesting correlation is that high PRA levels have been 
associated to tamoxifen resistance [326], and in paper III we found lower levels of 
PRA upon ERβ expression in T47-D cells, suggesting an alternative pathway for ERβ 
positive effects. We also described a possible mechanism behind this effect, where ERβ 
by decreasing PI3K/Akt and HER2/HER3 signalling and increasing PTEN levels 
sensitise breast cancer cells to tamoxifen. However, the picture is complex. So far we 
have not proven that these signalling pathways are directly linked to ERβ positive 
effects in response to tamoxifen in breast cancer cells. Therefore more studies are 
needed. Possible approaches would be using siRNA against PTEN, to see if the 
response of ERβ is affected, thereby targeting the responsible pathway. Are ERβ effects 
seen at the mRNA level direct transcriptional events? Are ratios of ERβ and ERα 
determinants for HER2 transcriptional regulation? These questions may be investigated 
using ChIP technology. Furthermore, how would ERβ plus tamoxifen affect cell 
viability upon HER2/HER3 activation (i.e. heregulin treatment)? Integrin linked kinase 
(ILK) is known to phosphorylate Akt at ser 473, providing another possible regulatory 
mechanism which could be investigated. Furthermore, HER3 binding proteins which 
negatively regulate HER3 may also be part of ERβ regulation of HER3. These proteins 
include NRDP1, LRIG-1 and Ebp1. Since expression of ERβ increased the potency of 
tamoxifen, it would also be interesting to investigate if ERβ expression would increase 
the potencies of tyrosine kinase inhibitors and monoclonal antibodies against the EGFR 
family. Interestingly, in paper III, we report that ERβ reduced the migratory potential 
of T47-D breast cancer cells. PTEN has also been shown to reduce cell migration 
[253], thereby suggesting another possible mechanism how ERβ affects migration by 
increasing PTEN levels. Furthermore, E-cadherin has been shown to regulate PTEN 
protein levels, thereby having a role in cell adhesion [327], and in paper II, we found 
that ERβ upregulates E-cadherin protein levels, further suggesting a possible 
mechanism how ERβ indirectly increases PTEN levels. 
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The emergence of endocrine resistance has fuelled the search for 
alternative therapies and for targets that can interfere with signalling pathways involved 
in endocrine resistance. These may lead to new strategies for combating ER positive 
breast cancers. In this respect, ERβ seems to be a good alternative candidate. To our 
knowledge, no studies have reported these molecular effects of ERβ, making it not only 
an intriguing target, but also a possible marker of choice for endocrine therapy. 
Therefore, measurement of not only ERα and PR, but also HER2, HER3, SRC-3, 
EGFR and ERβ in breast tumours could provide important information for predicting 
therapeutic responses. Further, since breast cancer is a heterogeneous disease, multiple 
markers would increase the potential for choosing the most optimal treatment.  
There were some major difficulties during the progress of my thesis. The 
first one was the lack of cell lines, specifically breast cancer cell lines, expressing 
endogenous ERβ. However, the use of different cell lines overexpressing ERβ allowed 
us to discover pathways regulated by ERβ in breast cancer. Ovexpression of a protein is 
not the most optimal approach to study an effect, not only due to its artificial nature, but 
also since possible unspecific effects, such as squelching, can emerge. However, in 
order to avoid unspecific effects, titration of the amounts of ERβ was done. Further, it 
is important to note that the cell line used in paper II (HC11) does express endogenous 
ERα and ERβ and results obtained with this cell line also point out an anti-proliferative 
role of ERβ [73] as well as its importance in maintaining  cell adhesion. Secondly, the 
lack of specific ERβ antibodies limited the potential to study ERβ, since measurement 
of mRNA does not always correlate with protein levels. Finally, the lack of ligands 
with high selectivity for ERβ was also an obstacle. The ligands for ERβ commercially 
available today do not have the highest selectivity, and when the selectivity is high, it 
usually favours ERα. Therefore improvement of design of ERβ specific ligands, as well 
as their general availability, is an important step to further allow us to investigate ERβ 
function. 
A better understanding of the role of ERβ in development and 
progression of breast cancer is emerging. Major questions regarding ERβ still remain 
unanswered. For instance, will therapy against ERβ apply to the clinic since levels of 
ERβ varies in patients? Another approach would be to reactivate ERβ in breast cancer. 
Since ERβ is thought to be silenced through DNA methylation, demethylating agents 
could be one approach to achieve its re-expression. In clinical trials, demethylating 
agents (azacitidine and decitabine) have been used on solid tumours, and given the 
success of these agents in treating myelodysplastic syndromes, further studies of their 
in vivo action is highly warranted. These agents need actively dividing cells in order to 
be incorporated, thus due to the short half-lifes of these drugs, slow-growing tumours 
may require a longer treatment, which would likely increase the toxic effects. 
Furthermore, these drugs are not very specific, thus may therefore result in expression 
of oncogenes. Another intriguing question concerns the role of unliganded ERβ in 
cellular function. In many of our studies ligand-independent effects were seen, however 
the mechanism behind this has not been investigated. Is it possible that ERβ is 
phosphorylated in our systems, thereby generating unliganded effects? I anticipate that 
targeting ERβ in breast cancer increases the therapeutic effects; therefore it would be 
exciting to try to understand the mechanism behind ERβ positive effects, however, 
what are the negative aspects in targeting ERβ? The cellular context also plays a role 
for ERβ function, with distinct functions in different cell types. The ratio of both ERs is 
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also important, therefore ligands would need to be not only tissue specific, but if 
possible also cell type specific.  
Many of the proteins and processes thought to be modulated by ERβ are 
subject to regulation by other pathways. Therefore it is of importance to consider that 
the response to ERβ may depend on the activity of these other signals, a situation that is 
important during tumour progression and therapy. The work presented in this thesis 
highlights the possibility of using ERβ as a prognostic marker with potential as a target 
in treatment of breast cancer. Although these results are encouraging, more work 
remains to be done. 
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